HS-­‐11-­‐421	
   Phase	
  III 	
  
	
  
A	
  Phase	
  III,	
  Randomized,	
  Double -­‐Blind,	
  Active -­‐Controlled,	
  Parallel	
  
Group,	
  Multi -­‐center	
  Trial	
  Assessing	
  the	
  Efficacy	
  and	
  Safety	
  of	
  a	
  Once -­‐
Weekly	
  and	
  Once -­‐Monthly,	
  Long -­‐Acting	
  Subcutaneous	
  Injectable	
  
Depot	
  of	
  Buprenorphine	
  (CAM2038)	
  in	
  T reatment	
  of	
  Adult	
  
Outpatients	
  with	
  Opioid	
  Use	
  Disorder 	
  
	
  
Statistical	
  Analysis	
  Plan 	
  (SAP) 	
  
	
  
	
  
Sponsor 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  
47	
  Hulfish	
  Street,	
  Suite	
  441 	
  
Princeton,	
  NJ	
  08542 	
  
Tel:	
  ( 609)	
  751-­‐5375 	
  
Fax:	
  ( 609)	
  921-­‐2156 	
  
	
  
	
  
Final	
   Version	
   1.01	
  
	
  4	
  Nov,	
  2016 	
  
	
  
	
  
	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   2	
  of	
  27	
   	
  SPO NSOR	
  APPROVAL 	
  
	
  
The	
  undersigned	
  have	
  reviewed	
  the	
  format	
  and	
  content	
  of	
  this	
   prospective	
   statistical	
  analysis	
  plan	
   (SAP)	
  
and	
  have	
  approved	
   it	
  for	
  use	
  to	
  analyze	
  the	
   HS-­‐11-­‐421	
  data .	
  
	
  
	
  
BRAEBURN	
  PHARMACEUTICALS 	
  	
  
	
  
Sonnie	
  Kim,	
  Pharm.D. 	
   	
  
	
  	
  Nov	
  4,	
  2016 	
  
Print	
  Nam e	
   	
  Signature 	
   	
  Date 	
  
	
  
	
  
	
  
	
  
STATISTICIAN 	
  
	
  
Michael	
  Chen 	
   	
  
	
  	
  Nov	
   4,	
  2016 	
  
Print	
  Name	
   	
  Signature	
   	
  Date 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   3	
  of	
  27	
   	
  TABLE	
  OF	
  CONTENTS 	
  
1.0	
  DOCUMENT	
  HISTORY 	
  ................................ ................................ ................................ ........................... 	
  5	
  
2.0	
  LIST	
  OF	
  ABBREVIATION S	
  ................................ ................................ ................................ .................... 	
  5	
  
3.0	
  INTRODUCTION 	
  ................................ ................................ ................................ ................................ ......	
  6	
  
4.0	
  STUDY	
  DESCRIPTION 	
  ................................ ................................ ................................ ............................ 	
  6	
  
4.1	
  Study	
  Objectives 	
  ................................ ................................ ................................ ...................... 	
  6	
  
4.2	
  Study	
  Treatments 	
  ................................ ................................ ................................ .................... 	
  7	
  
4.3	
  Study	
  Design 	
  ................................ ................................ ................................ .............................. 	
  7	
  
4.4	
  Randomization	
  and	
  Blinding 	
  ................................ ................................ ............................... 	
  8	
  
5.0	
  ANALYSIS	
  POPULATIONS 	
  ................................ ................................ ................................ .................... 	
  8	
  
5.1	
  Safety	
  Population 	
  ................................ ................................ ................................ .................... 	
  8	
  
5.2	
  Intent -­‐‑to-­‐‑Treat	
  Population 	
  ................................ ................................ ................................ ..	
  9	
  
5.3	
  modified	
  intent -­‐‑to-­‐‑treat	
  population 	
  ................................ ................................ ................. 	
  9	
  
5.4	
  per	
  protocol	
  Pop ulation 	
  ................................ ................................ ................................ ........	
  9	
  
6.0	
  GENERAL	
  CONVENTIONS 	
  ................................ ................................ ................................ ..................... 	
  9	
  
6.1	
  Definition	
  of	
  Baseline 	
  ................................ ................................ ................................ ............. 	
  9	
  
6.2	
  Software 	
  ................................ ................................ ................................ ................................ ......	
  9	
  
6.3	
  Changes	
  to	
  Planned	
  Analyses 	
  ................................ ................................ .............................. 	
  9	
  
7.0	
  DESCRIPTION	
  OF	
  THE	
  S TUDY	
  POPULATIONS 	
  ................................ ................................ ............ 	
  10	
  
7.1	
  Disposition 	
  ................................ ................................ ................................ ............................... 	
  10	
  
7.2	
  Demographic	
  and	
  Baseline	
  Characteristics 	
  ................................ ................................ ..	
  10	
  
7.3	
  Medical	
  History 	
  ................................ ................................ ................................ ...................... 	
  10	
  
8.0	
  PRIOR	
  AND	
  CONCOMITAN T	
  MEDICATIONS 	
  ................................ ................................ ................ 	
  10	
  
9.0	
  EFFICACY	
  ANALYSES 	
  ................................ ................................ ................................ ........................... 	
  11	
  
9.1	
  Prim ary	
  Efficacy	
  VARIABLE	
   –	
  Responder	
  rate 	
  ................................ ............................. 	
  11	
  
9.1.1 	
  derivation	
  of	
  response	
  rate 	
  ................................ ................................ ................................ 	
  11	
  
9.1.2 	
  Primary	
  Analysis 	
  ................................ ................................ ................................ ..................... 	
  12	
  
9.1.3 	
  missing	
  value	
  imputation 	
  ................................ ................................ ................................ ....	
  12	
  
9.2	
  Secondary	
  Efficacy	
   VARIABLES 	
  ................................ ................................ ......................... 	
  12	
  
9.2.1 	
  Cumulative	
   distribution	
  function	
  (C DF)	
  of	
  percent	
  samples	
  that	
  are	
  negative	
  
for	
  illicit	
  opioids	
  (Weeks	
  5 -­‐‑25)	
  ................................ ................................ ......................... 	
  13	
  
9.2.2 	
  time	
  to	
  sustained	
  abstinence	
  of	
  opioid	
  use 	
  ................................ ................................ .	
  13	
  
9.2.3 	
  Percent	
  of	
  subjects	
  remaining	
  in	
  the	
  study	
  (Retention	
   Rate) 	
  .............................. 	
  13	
  
9.3	
  EXPLORATORY	
  Efficacy	
  VARIABLES 	
  ................................ ................................ ............... 	
  13	
  
9.3.1 	
  Response 	
  rate	
  (RR)	
  for	
  phase	
  1 	
  ................................ ................................ ........................ 	
  14	
  
9.3.2 	
  Response	
  rate	
  (RR)	
  for	
  phase	
  2 	
  ................................ ................................ ........................ 	
  14	
  
9.3.3 	
  percentage	
  negative	
  urine	
  samples	
  in	
  p hase	
  1	
  (weeks	
  3 -­‐‑13)	
  ............................. 	
  14	
  
9.3.4 	
  percentage	
  negative	
  urine	
  samples	
  in	
  phase	
  2	
  (weeks	
  14 -­‐‑25)	
  ........................... 	
  14	
  
9.3.5 	
  Percent	
  of	
  Subjects	
  with	
  no	
  Ill icit	
  Opioid	
  Use	
  by	
  time	
  point 	
  ................................ 	
  14	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   4	
  of	
  27	
   	
  9.3.6 	
  Cumulative	
  Percentage	
  of	
  SUBJECTS	
  with	
  Evidence	
  of	
  No	
  Illicit	
  Opioid	
  Use	
  by	
  
time	
  point	
  after	
  2	
  months	
  of	
  treatment 	
  ................................ ................................ ........	
  15	
  
9.3.7 	
  Percent	
  of	
  Subjects	
  with	
  No	
  Self -­‐‑Reported	
  Illicit	
  opioid	
  Use	
  by	
  time	
  point 	
  ..	
  15	
  
9.3.8 	
  Percent	
  of	
  subjects	
  meeting	
  criteria	
  of	
  stability	
  by	
  time	
  point 	
  ........................... 	
  15	
  
9.3.9 	
  Measures	
  of	
  craving	
  (VAS) 	
  ................................ ................................ ................................ ..	
  16	
  
9.3.10 	
  Measures	
  of	
  withdrawal 	
  SYMPTOMS 	
  ................................ ................................ ............. 	
  16	
  
9.3.11 	
  Percent	
  of	
  subjects	
  without	
  evidence	
  of	
  using	
  other	
  drugs	
  of	
  abuse	
  by	
  time	
  
point 	
  ................................ ................................ ................................ ................................ .............. 	
  17	
  
9.3.12 	
  Supplemental	
  BPN	
  use 	
  ................................ ................................ ................................ .........	
  17	
  
9.3.13 	
  Additional	
  supplemental	
  counseling 	
  ................................ ................................ .............. 	
  17	
  
9.3.14 	
  Measures	
  of	
  morning	
  need	
  to	
  use/desire	
  to	
  use	
  (VAS) 	
  ................................ .......... 	
  17	
  
9.4	
  Interim	
  Analyses 	
  ................................ ................................ ................................ .................... 	
  17	
  
9.5	
  Adjustments	
  for	
  Multiplicity 	
  ................................ ................................ ............................. 	
  17	
  
9.6	
  Power	
  and	
  Sample	
  Size	
  Justification 	
  ................................ ................................ ............... 	
  18	
  
10.0 	
  SUMMARIES	
  OF	
  MEASURE S	
  OF	
  SAFETY 	
  ................................ ................................ ........................ 	
  18	
  
10.1 	
  Extent	
  of	
  Exposure 	
  ................................ ................................ ................................ ................ 	
  18	
  
10.2 	
  Adverse	
  Events 	
  ................................ ................................ ................................ ....................... 	
  18	
  
10.3 	
  Laboratory	
  Assessments 	
  ................................ ................................ ................................ .....	
  19	
  
10.4 	
  Vital	
  Signs 	
  ................................ ................................ ................................ ................................ .	
  20	
  
10.5 	
  Physical	
  Exam ination 	
  ................................ ................................ ................................ ........... 	
  20	
  
10.6 	
  12-­‐‑Lead	
  Electrocardiogram	
  (ECG) 	
  ................................ ................................ ................... 	
  20	
  
10.7 	
  injection	
  Site	
  Examination 	
  ................................ ................................ ................................ .	
  21	
  
11.0 	
  IDENTIFICATION	
  AND	
  S UMMARY	
  OF	
  PROTOCOL	
  D EVIATIONS 	
  ................................ ........... 	
  21	
  
12.0 	
  DATA	
  QUALITY	
  ASSURAN CE	
  ................................ ................................ ................................ ............ 	
  21	
  
13.0 	
  REFERENCES 	
  ................................ ................................ ................................ ................................ .......... 	
  21	
  
14.0 	
  APPENDICES 	
  ................................ ................................ ................................ ................................ .......... 	
  22	
  
14.1 	
  Appendix	
  A	
   -­‐‑	
  Imputation	
  Algorithm	
  for	
  Partial	
  and	
  Missing	
  Dates 	
  ...................... 	
  22	
  
14.2 	
  Appendix	
  B	
   –	
  List	
  of	
  tables,	
  listings,	
  and	
  figures 	
  ................................ ......................... 	
  23	
  
	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   5	
  of	
  27	
   	
  	
  
1.0   DOCUMENT	
  HISTORY 	
  
Version 	
   Date	
   	
   Changes	
  made	
  since	
  previous	
  version 	
  
0.01 	
   27	
  Jan ,	
  201 6	
   First	
  draft 	
  
1.00	
   20	
  October, 	
  2016 	
   Final	
  after	
  receiving	
  FDA’ s	
  comments	
  dated	
  on	
   01	
  Sept	
  2016 	
  
1.01	
   4	
  November,	
  2016 	
   Due	
   to	
   differences	
   in	
   analyses	
   requested	
   by	
   the	
   FDA	
   and	
   EMA	
  
and	
  to	
  avoid	
  confusion ,	
  as	
  stated	
  in	
  the	
  protocol,	
  two	
   SAPs	
  will	
  
be	
   prepared,	
   one	
   for	
   FDA	
   submission	
   and	
   one	
   for	
   the	
   EMA	
  
submission.	
   	
   Additi onally,	
   this	
   version	
   incorporates	
   FDA’s	
  
comments	
   dated	
   on	
   04	
   Nov	
   2016.	
   Version	
   1.00	
   was	
   revised	
   to	
  
reflect	
   statistical	
   analysis	
   plan	
   for	
   the	
  US	
   FDA	
   submission. 	
  	
  The	
  
EMA	
   specific	
   variables	
   are	
   removed	
   from	
   Version	
   1.00.	
   	
   No	
  
analysis	
  methodologies	
  are	
  change d	
  from	
  Version	
  1.00. 	
  
	
  
2.0   LIST	
  OF	
  ABBREVIATION S	
  
Abbreviation 	
   Definition 	
  
AE	
   Adverse	
   Event 	
  
ANCOVA	
   Analysis	
  of	
  Covariance 	
  
ANOVA	
   Analysis	
  of	
  Variance 	
  
BMI	
   Body	
  Mass	
  Index	
   	
  
BPN	
   Buprenorphine	
  or	
  Buprenorphine/Naloxone	
  
CDF	
   Cumulative	
  Distribution	
  Function 	
  
COWS 	
   Clinical	
  Opi ate	
  Withdrawal	
  Scale 	
  
CRF	
   Case	
  Report	
  Form	
  (may	
  include	
  electronic	
  data	
  capture	
  systems	
  or	
  paper	
  forms) 	
  
FID	
   First	
  Injection	
  Date 	
  
ICH	
   International	
   Council	
  for 	
  Harmonisation 	
  
ITT	
   Intent -­‐to-­‐Treat	
  
LD	
   Last	
  Date	
  in	
  the	
  study 	
  
LOCF 	
   Last	
  Observati on	
  Carried	
  Forward 	
  
MedDRA 	
   Medical	
  Dictionary	
  for	
  Regulatory	
  Activities 	
  
mg	
   Milligram 	
  
mITT 	
   Modified	
  Intent -­‐to-­‐Treat 	
  
PT	
   MedDRA	
  Preferred	
  Term 	
  
RR	
   Response	
  Rate	
  
SAE	
   	
   Serious	
   Adverse	
   Event 	
  
SAP	
   Statistical	
  Analysis	
  Plan 	
  
SC	
   Subcutaneous 	
  
SD	
   Standard	
  Deviat ion	
  
SL	
   Sublingual	
   	
  
SOC	
   MedDRA	
  System	
  Organ	
  Class 	
  
SOWS	
   Subjective	
  Opi ate	
  Withdrawal	
  Scale 	
  
TEAE 	
   Treatment -­‐Emergent	
   Adverse	
   Event 	
  
VAS	
   Visual	
  Analog	
  Scale 	
  
	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   6	
  of	
  27	
   	
  	
  
3.0   INTRODUCTION 	
  
This	
  statistical	
  analysis	
  plan	
  (SAP)	
   is	
  based	
  on	
   Protocol	
   HS-­‐11-­‐421	
  Amendment	
   5,	
  dated	
  on	
   November	
  3 ,	
  
2016 .	
  
The	
  purpose	
  of	
  this	
  document	
  is	
  to	
  provide	
  details	
  on	
   study	
  populations	
  and	
  on	
   how	
  the	
  variables	
  will	
  be	
  
derived,	
  how	
  missing	
  data	
  will	
  be	
  handled,	
  as	
  well	
  as	
  details	
  on	
  statistical	
  method ologie s	
  to	
  be	
  used	
   to	
  
analyze	
  the	
   safety	
  an d	
  efficacy	
   data	
  from	
  the	
  study.	
  	
   	
  
	
  
The	
  document	
  may	
  evolve	
  over	
  time,	
  for	
  example,	
  to	
  reflect	
  the	
  requirements	
  of	
  protocol	
  amendments 	
  
or	
  regulatory	
  requests .	
  	
  However,	
  the	
  final	
  SAP	
  must	
  be	
  finalized,	
  approved 	
  by	
  the	
  Sponsor ,	
  and	
  placed	
  
on	
   file	
   before	
   data base	
   is	
   locked	
   and	
   treatment	
   codes	
   are	
   unblinded .	
   	
  Deviations	
   from	
   the	
   approved	
  
plan	
  will	
  be	
  noted	
  in	
  the	
  clinical	
  study	
  report. 	
  
	
  
The	
  primary	
  endpoint	
  response	
  rate	
  will	
  be	
  used	
  to	
  address	
  the	
  regulatory	
  requirements	
  as	
  outlined	
  by	
  
the	
   US	
   Food	
   and	
   Drug	
   Adm inistration	
   (FDA).	
   Specifically ,	
   the	
   FDA	
   requested	
   an	
   alternative	
   primar y	
  
efficacy	
   responder	
   definition 	
  on	
   September	
   1,	
   2016 ,	
   which	
   have	
   been	
   incorporated	
   in	
   this	
   final	
   SAP.	
  
Additionally,	
  the	
  FDA	
  provided	
  comments	
  on	
  November	
  4,	
  2016	
  and	
  recommended	
  a	
  NI	
  m argin	
  of	
  10%	
  
points	
  to	
  be	
  reasonable	
  NI	
  margin	
  for	
  the	
  study.	
  This	
  change	
  is	
  reflected	
  in	
  this	
  final	
  SAP.	
  	
   	
  
	
  
The	
   European	
   Medical	
   Agency	
   (EMA)	
   has	
   requested	
   percent	
   negative	
   urine	
   samples	
   as	
   the	
   primary	
  
endpoint	
  and	
  retention	
  rate	
  as	
  key	
  secondary	
  endpoint .	
  These	
  requests	
  are	
  addressed	
  in	
  a	
  separate	
  SAP	
  
for	
   EMA	
   submission .	
  	
  The	
  variables	
  related	
  to	
  the	
  percentage	
  of	
  urine	
  sample	
  negative 	
  (EMA	
   specific	
  
variables)	
  are	
  removed	
  from	
  Version	
  1.01	
  that	
  is	
  for	
  FDA	
  submission. 	
  
	
  
	
  
4.0   STUDY	
   DESCRIPTION 	
  
4.1   STUDY	
  OBJECTIVES 	
  
The	
  primary	
  objective	
  of	
  the	
  study	
   is	
  to	
  demonstrate	
  non -­‐inferiority	
  of	
   the	
  CAM2038	
   buprenorphine	
  
(BPN)	
   treatment	
   arm	
   as	
  compared	
  to	
   the	
  sublingual	
  (SL)	
  BPN	
   treatment	
  arm	
   in	
  treating	
   adult	
  
outpatients	
  with	
  opioid	
  use	
  disorder,	
  as	
  measured	
  by	
  the	
  primary	
  eff icacy	
  measure	
  of	
  response	
  rate	
  
(RR). 	
  
The	
  secondary	
  objective s	
  of	
  the	
  study	
   are:	
  
•  To	
  evaluate	
  the	
  efficacy	
  of	
  CAM2038	
  compared	
  to	
  SL	
  BPN	
  in	
  adult	
  outpatients	
  with	
  opio id	
  use	
  
disorder,	
  as	
  measured	
  by	
  cumulative	
  distribution	
  function 	
  of	
  percent	
  negative	
  urines 	
  (supported	
  
by	
  self -­‐reported	
   opioid	
  use 	
  results)	
  between	
  Weeks	
  5	
  and	
  24 .	
  
•  To	
  evaluate	
  the	
  efficacy	
  of	
  CAM2038	
  compared	
  to	
  SL	
  BPN	
  in	
  adult	
  outpatients	
  with	
  opioid	
  use	
  
disorder,	
  as	
  measured	
  by	
  the	
  secondary	
  efficacy	
  measure	
  of	
  time	
  to	
  sustained	
  abstinence	
  fro m	
  
illicit	
  opioid	
  use. 	
  
•  To	
  evaluate	
  the	
  efficacy	
  of	
  CAM2038	
  compared	
  to	
  SL	
  BPN	
  in	
  adult	
  outpatients	
  with	
  opioid	
  use	
  
disorder,	
  as	
  measured	
  by	
  the	
  secondary	
  efficacy	
  measure	
  retention	
  rate. 	
  
•  To	
  evaluate	
  the	
  efficacy	
  of	
  CAM2038	
  compared	
  to	
  SL	
  BPN	
  in	
  adult	
  outpat ients	
  with	
  opioid	
  use	
  
disorder,	
  as	
  measured	
  by	
  the	
  exploratory	
  efficacy	
  measures. 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   7	
  of	
  27	
   	
  •  To	
  evaluate	
  the	
  safety	
  of	
  CAM2038	
  in	
  adult	
  outpatients	
  with	
  opioid	
  use	
  disorder. 	
  
	
  
4.2   STUDY	
  TREATMENT S	
  	
  
In	
  this	
   double -­‐blind	
   and	
   double -­‐dummy	
   study,	
   subjects	
  will	
  be	
  randomized	
  t o	
  one	
  of	
  two	
  treatment	
  
groups	
  in	
  a	
  1:1	
  ratio: 	
  
Treatment	
  Group	
   1:	
  SL	
  BPN	
  tablets	
  +	
  placebo	
  subcutaneous	
  (SC)	
  injections 	
  
Treatment	
  Group	
   2:	
  CAM2038	
  SC	
  injections	
  +	
  SL	
  placebo	
  tablets 	
  
4.3   STUDY	
  DESIGN 	
  
This	
  is	
  a	
  randomized,	
  double -­‐blind,	
  double -­‐dummy,	
  active -­‐contr olled,	
  parallel	
  group	
  multi -­‐center	
  trial,	
  
designed	
  to	
  evaluate	
  the	
  non -­‐inferiority	
  of	
  CAM2038	
  compared	
  to	
  an	
  existing	
  standard	
  of	
  care	
  (SL	
  BPN)	
  
in	
   initiation	
   and	
   maintenance	
   treatment	
   with	
   BPN.	
   The	
   trial	
   will	
   involve	
   4	
   phases:	
   Screening,	
   Phase	
   1	
  
(weekly	
  vi sits),	
  Phase	
  2	
  (monthly	
  visits),	
  and	
  Follow -­‐up.	
  
	
  
Following	
  Screening	
  and	
  confirmation	
  of	
  eligibility,	
  subjects	
  will	
  be	
  randomized	
  to	
  one	
  of	
  two	
  treatment	
  
groups	
  in	
  a	
  1:1	
  ratio:	
   	
  
	
  
•  Group	
  1:	
  SL	
  BPN	
  tablets	
  +	
  placebo	
  SC	
  injections 	
  
•  Group	
  2:	
  CAM2038	
  SC	
  injection s	
  +	
  SL	
  placebo	
  tablets 	
  
	
  
Following	
   randomization,	
   subjects	
   will	
   undergo	
   initiation	
   of	
   BPN	
   treatment	
   with	
   either	
   SL	
   BPN	
   or	
   SC	
  
CAM2038	
  q1w,	
  and	
  participate	
  in	
  weekly	
  visits	
  for	
  12	
  weeks	
  (Phase	
  1).	
  After	
  Week	
  12,	
  subjects	
  will	
  be	
  
transitioned	
  to	
  Phase	
  2	
  with	
  m onthly	
  visits.	
  During	
  Phase	
  2,	
  subjects	
  in	
  Group	
  1	
  will	
  continue	
  treatment	
  
with	
  monthly	
  dispensing	
  of	
  daily	
  SL	
  BPN	
  treatment	
  and	
  monthly	
  placebo	
  SC	
  injections,	
  and	
  subjects	
  in	
  
Group	
   2	
   (receiving	
   CAM2038	
   q1w)	
   will	
   be	
   transferred	
   to	
   monthly	
   injections	
   of	
   CAM 2038	
   q4w	
   and	
  
monthly	
   dispensing	
   of	
   daily	
   SL	
   placebo.	
   Subjects	
   will	
   participate	
   in	
   6	
   visits	
   during	
   the	
   12	
   weeks	
   of	
  
Phase 	
  2;	
   3	
   scheduled	
   monthly	
   visits	
   and	
   3	
   random	
   urine	
   toxicology	
   visits.	
   At	
   each	
   random	
   urine	
  
toxicology	
   visit,	
   subject’s	
   self -­‐reported	
   illic it	
   use 	
  will	
   be 	
  collected .	
   After	
   Phase	
   2,	
   subjects	
   will	
   be	
  
followed -­‐up	
  for	
  4	
  weeks. 	
  
	
  
A	
  total	
  of	
  18	
  opioid	
  urine	
  toxicology	
  samples	
  will	
  be	
  collected	
  during	
  Phase	
  1	
  and	
  Phase	
  2	
  of	
  the	
  trial,	
  
whereof	
  12	
  samples	
  will	
  be	
  collected	
  at	
  the	
  scheduled	
  weekly	
  visits 	
  during	
  Phase	
  1.	
  A	
  total	
  of	
  6	
  opioid	
  
urine	
  toxicology	
  samples	
  will	
  be	
  collected	
  during	
  the	
  12	
  weeks	
  of	
  Phase	
  2	
  (3	
  at	
  the	
  scheduled	
  monthly	
  
visits	
   and	
   3	
   at	
   random	
   urine	
   toxicology	
   visits).	
   A	
   self -­‐report	
   of	
   drug	
   use	
   will	
   accompany	
   every	
   urine	
  
toxicology	
  test .	
  
	
  
Subjects	
   who	
   complete	
   the	
   24	
   weeks	
   of	
   treatment	
   (i.e.,	
   Phase	
   1	
   and	
   Phase	
   2)	
   will	
   be	
   transitioned	
   to	
  
standard	
  of	
  care	
  (e.g.,	
  SL	
  BPN)	
  and	
  be	
  followed	
  up	
  for	
  4	
  weeks. 	
  
	
  
All	
  subjects	
  will	
  be	
  blinded	
  to	
  their	
  treatment	
  group	
  assignment,	
  as	
  will	
  all	
  trial	
  staf f	
  with	
  the	
  exception	
  
of	
  the	
  clinician(s)/staff	
  performing	
  the	
  SC	
  injections	
  and	
  designated	
  personnel	
  who	
  will	
  be	
  responsible	
  
for	
  drug	
  accountability	
  (i.e.,	
  counting	
  the	
  active	
  and	
  placebo	
  SL	
  BPN	
  returned	
  tablets). 	
  
	
  	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   8	
  of	
  27	
   	
  To	
  ensure	
  adequate	
  enrollment	
  and	
  addres s	
  potential	
  inconvenience	
  to	
  subjects,	
  all	
  subjects	
  (regardless	
  
of	
   randomized	
   group)	
   will	
   receive	
   appropriate	
   compensation	
   for	
   time	
   and	
   travel	
   expenses	
   related	
   to	
  
attendance	
  at	
  trial	
  visits.	
  All	
  costs	
  of	
   study	
  related	
   medications	
  and	
  counseling	
  will	
  also	
  b e	
  covered. 	
  
Investigators	
   will	
   be	
   instructed	
   to	
   use	
   manual -­‐guided	
   psychosocial	
   counseling	
   for	
   trial	
   subjects	
  
throughout	
  the	
  trial	
  period. 	
  	
  	
  
4.4   RANDOMIZATION	
  AND	
  BL INDING 	
  
Randomization	
   will	
   be	
   used	
   to	
   avoid	
   bias	
   in	
   the	
   assignment	
   of	
   subjects	
   to	
   treatment	
   sequen ces,	
   to	
  
increase	
   the	
   likelihood	
   that	
   known	
   and	
   unknown	
   subject	
   attributes	
   (e.g.,	
   demographics,	
   baseline	
  
characteristics)	
  are	
  evenly	
  balanced	
  across	
  treatment	
  groups,	
  and	
  to	
  enhance	
  the	
  validity	
  of	
  statistical	
  
comparisons	
  across	
  treatment	
  groups. 	
  
Subjects	
   w ho	
   have	
   provided	
   written	
   informed	
   consent	
   will	
   be	
   assigned	
   a	
   unique	
   number	
   in	
   the	
  
screening	
  process.	
  This	
  number	
  will	
  be	
  used	
  to	
  identify	
  the	
  subject	
  throughout	
  the	
  study. 	
  
Subjects	
  who	
  have	
  met	
  the	
  eligibility	
  criteria	
  ( outlined	
  in	
   Section	
  8 	
  of	
  the	
  clinica l	
  trial	
  protocol )	
  will	
  be	
  
randomized	
   to	
   one	
   of	
   the	
   2	
   treatment	
   groups	
   i n	
   a	
   1:1	
   ratio	
   (Treatment	
   Group	
   1 :	
  SL	
   BPN	
   tablets	
   +	
  
placebo	
  SC	
  injections 	
  or	
  Treatment	
  Group	
  2 :	
  CAM2038	
  SC	
  injections	
  +	
  SL	
  placebo	
  tablets ).	
  Due	
  to	
  the	
  
size	
  of	
  the	
  study,	
  it	
  is	
  expected	
   that	
  subjects	
  will	
  be	
  balanced	
  for	
  various	
  other	
  baseline	
  factors,	
  including	
  
age.	
  
Once	
  any	
  subject	
  number	
  or	
  randomization	
  number	
  is	
  assigned,	
  it	
  cannot	
  be	
  reassigned	
  to	
  any	
  other	
  
subject.	
  This	
  study	
  will	
  use	
  central	
  randomization,	
  as	
  described	
  in	
  Section	
   10.2	
  of	
  the	
  protocol. 	
  
In	
   order	
   to	
   reduce	
   the	
   potential	
   for	
   bias	
   in	
   the	
   study,	
   treatment	
   group	
   assignments	
   will	
   be	
   double -­‐
blinded.	
  The	
  subject,	
  investigational	
  site	
  personnel,	
  Sponsor,	
  and	
  Sponsor	
  designees	
  directly	
  involved	
  in	
  
the	
   conduct	
   and/or	
   monitoring 	
  of	
   this	
   study	
   will	
   not	
   be	
   aware	
   of	
   the	
   treatment	
   group	
   assignments.	
  
Sublingual	
  BPN	
  tablets	
  used	
  during	
  the	
  study	
  will	
  have	
  a	
  nearly -­‐matching	
  placebo.	
   	
  
Under	
   normal	
   circumstances,	
   the	
   blind	
   will	
   not	
   be	
   broken	
   until	
   all	
   participants	
   have	
   completed	
  
treatment .	
  In	
  case	
  of	
  emergency,	
  and	
  only	
  if	
  the	
  information	
  is	
  required	
  by	
  the	
  Investigator	
  to	
  ensure	
  
subject’s	
  safety	
  in	
  managing	
  a	
  medical	
  condition,	
  the	
  treatment	
  may	
  be	
  unblinded	
  at	
  the	
  site	
  by	
  using	
  a	
  
code	
  break	
  module.	
  The	
  code	
  break	
  module	
  will	
  be	
  provided	
   by	
  the	
  Sponsor	
  or	
  designee.	
  If	
  possible,	
  the	
  
Investigator	
   should	
   contact	
   the	
   Sponsor	
   prior	
   to	
   unblinding	
   and	
   after	
   any	
   actions	
   have	
   been	
   taken.	
  
Whenever	
  a	
  treatment	
  sequence	
  is	
  prematurely	
  unblinded,	
  the	
  reason,	
  date	
  and	
  time	
  of	
  the	
  unblinding,	
  
and	
   the	
   ind ividual	
   who	
   broke	
   the	
   blind	
   must	
   be	
   documented.	
   Individual	
   code	
   breaks	
   will	
   result	
   in	
  
withdrawal	
  of	
  the	
  participant	
  from	
  the	
  study. 	
  	
  
5.0   ANALYSIS	
  POPULATIONS 	
  
5.1   SAFETY	
  POPULATION 	
  
The	
   safety	
   population	
   will	
   include	
   all	
   subjects	
   who	
   have	
   any	
   dose	
   of	
   SL	
   BPN/placebo	
   or	
  SC	
  
CAM2038/placebo	
   injection .	
  Analyses	
   based	
   on	
   this	
   population	
   will	
   group	
   subjects	
   according	
   to	
   the	
  
treatment	
   they	
   actually	
   received	
   regardless	
   of	
   the	
   treatment	
   they	
   were	
   randomized	
   to	
   receive. 	
  All	
  
safety	
  analyses	
  will	
  use	
  the	
  safety	
  population. 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   9	
  of	
  27	
   	
  5.2   INTENT -­‐‑TO-­‐‑TREAT	
  POPULATION 	
  
The	
  Intent -­‐to-­‐Treat	
  (ITT)	
  population	
  will	
  consist	
  of	
  all	
   randomized	
   subjects. 	
  The	
  primary	
  efficacy	
  analys es	
  
will	
  be	
  based	
  on	
  the	
  ITT	
  population. 	
  
5.3   MODIFIED	
  INTENT -­‐‑TO-­‐‑TREAT	
  POPULATION 	
  
The	
   modified	
   Intent -­‐to-­‐Treat	
  ( mITT)	
  population	
  will	
  co nsist	
  of	
  all	
  randomized	
  subjects 	
  who	
  received 	
  any	
  
SL	
  BPN/placebo	
  or	
   SC	
  CAM2038/placebo	
  injection .	
  	
  It	
  is	
  expected	
  that	
  the	
  ITT	
  and	
  mITT	
  population	
  will	
  
be	
  nearly	
  identical.	
  	
  The	
  results	
  for	
  the	
  mITT	
  population	
  will	
  not	
  be	
  presented	
  if	
  the	
  two	
  populat ions	
  a re	
  
differed	
  by	
  less	
  than	
  five	
  (5)	
  subjects 	
  as	
  in	
  this	
  case	
  the	
  conclusions	
  based	
  on	
  the	
  two	
  populations	
  should	
  
be	
  identical .	
  
5.4   PER	
  PROTOCOL	
  POPULAT ION	
  
The	
   Per	
   Protocol	
   population	
   will	
   include	
   all	
   subjects	
   in	
   the	
   ITT	
   population	
   with	
   no	
   major	
   protocol	
  
violatio ns.	
  Major	
   protocol	
   violation	
   criteria	
   will	
   be	
   established	
   prior	
   to	
   the	
   data	
   base	
   lock.	
   Protocol	
  
deviations	
  will	
  be	
  presented	
  in	
  the	
  clinical	
  study	
  report. 	
  Efficacy	
  analyses	
   may	
  also	
  be	
  performed	
  based	
  
on	
  the	
  per	
  protocol	
  population.	
  	
   	
  
	
  
6.0   GENERAL	
  CONVENTIONS 	
  
Unless	
   otherwise	
   stated,	
   all	
   analyses	
   will	
   be	
   performed	
   using	
   SAS	
   Version	
   9 .2	
   or	
   higher 	
  and	
   all	
  
hypothesis	
  tests	
  will	
  be	
  conducted	
  at	
  a	
  two -­‐sided	
  significance	
  level	
  of	
  0.05. 	
  P-­‐values	
  will	
  be	
  presented	
  
with	
  3	
  decimals	
  and	
  p -­‐values	
  that	
  are	
  less	
  than	
  0.001	
  w ill	
  be	
  presented	
  as	
  <0.001. 	
  
	
  
Continuous	
   (non	
   survival	
   related)	
   data	
   will	
   be	
   summarized	
   using	
   descriptive	
   statistics:	
   number	
   of	
  
observations	
   (n),	
   mean,	
   standard	
   deviation	
   (SD),	
   median,	
   minimum,	
   and	
   maximum.	
   Frequencies	
   and	
  
percentages	
  will	
  be	
  used	
   to	
  summar ize	
  categorical	
  (discrete)	
  data.	
   Presentations	
  of 	
  categorical	
  data	
  will	
  
generally	
   suppress 	
  percentages 	
  for	
   items	
   where	
   the 	
  count	
   is	
   zero	
   in	
   order	
   to	
   draw	
   attention	
   to	
   the	
  
nonzero	
  counts. 	
  In	
  general,	
  mean,	
  standard	
  deviation,	
  median,	
  minimum,	
  maximum,	
  and	
  p ercentages	
  
will	
  be	
  presented	
  with	
  one	
  decimal. 	
  
	
  
Unless	
   otherwise	
   stated,	
   c onfidence	
   intervals,	
   when	
   presented,	
   will	
   be	
   constructed	
   at	
   the	
   two-­‐sided	
  
95%	
   level.	
   For	
   binomial	
   variables,	
   the	
   95%	
   confidence	
   intervals	
   will	
   be	
   constructed	
   using	
   the	
   normal	
  
approxi mation	
   without	
  continuity	
  correction. 	
  
	
  
Data	
  listings	
  will	
  present	
  all	
   data	
  collected	
  on	
   case	
  report	
  forms	
  ( CRFs )	
  by	
  study	
  drug,	
  center,	
  and	
   subject 	
  
number. 	
  Unless	
  otherwise	
  stated	
  data	
  will	
  be	
  presented	
  by	
  treatment	
  and	
  overall .	
  
6.1   DEFINITION	
  OF	
  BASELI NE	
  
Unle ss	
  otherwise	
  stated ,	
  the	
  last	
  observed	
  measurement	
   prior	
  to	
  or	
   on	
  the	
  date	
  of	
  randomization 	
  will	
  
be	
   consi dered	
   the	
   baseline	
   measurement. 	
  If	
   multiple	
   observations	
   are	
   made	
   during	
   baseline,	
   the	
  
baseline	
  will	
  be	
  defined	
  as	
  average	
  of	
  the	
  observations	
  obtained 	
  during	
  the	
  baseline	
  phase. 	
  
6.2   SOFTWARE 	
  
Analyses	
  will	
  be	
  conducted	
  using	
  SAS	
  Version	
  9 .2	
  or	
  higher .	
  	
  	
  
6.3   CHANGES	
  TO	
  PLANNED	
  A NALYSES 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   10	
  of	
  27	
   	
  Draft	
  versions	
  of	
  the	
  SAP	
  will	
  be	
  numbe red	
  sequentially	
  as	
  Version	
  0.0 i.	
  The	
  final	
  approved	
  version	
  will	
  
be	
  numbered	
  as	
  Ver sion	
  1 .00.	
   Revisions	
  after	
  the	
  “Final”	
  version	
  will	
   be	
  numbered	
  as	
  Version	
  1.0x.	
   The	
  
Clinical	
   Study	
   Report	
   will	
   document	
   any	
   changes	
   made	
   after	
   the	
   final	
   version	
   approved	
   before	
  
unblinding .	
  
	
  
7.0   DESCRIPTION	
  OF	
  THE	
   STUDY	
  POPULATION S	
  
All	
   tables,	
   figures,	
   and	
   listings	
   must	
   include	
   a	
   population	
   descriptor	
   (e.g.,	
   ITT	
   population,	
   mITT	
  
population,	
   safety 	
  population, 	
  or	
  per	
  protocol 	
  population )	
  in	
  the	
  title .	
  
7.1   DISPOSITION 	
  
Subject 	
  disposition 	
  summaries	
   will	
   be	
   presented	
   by	
   treatment	
   arm	
   and	
   will	
   include	
   the	
   number 	
  of	
  
subject s	
  randomized,	
  the	
  number 	
  and	
  percentage	
  of	
   randomized	
   subject s	
  in	
  the	
   safety,	
   ITT,	
  mITT	
   and	
  
per	
  protocol	
  (if	
  applicable)	
   population s,	
  as	
  well	
  as	
  the	
  number	
  and	
  percentage	
  of	
  subjects	
  who	
  complete	
  
the	
  study .	
  The	
  summaries	
  will	
  also	
  include	
   the	
  reasons	
  for	
   early	
  discontinuation	
   from	
  the 	
  study. 	
  	
  	
  
	
  
Disposition	
   summaries	
   will	
   be	
   presented	
   for	
   safety,	
   ITT,	
  mITT, 	
  and	
   per	
   protocol	
   populations	
   (if	
  
applicable)	
   separately. 	
  
7.2   DEMOGRAPHIC	
  AND	
  BASE LINE	
  CHARACTERISTICS 	
  
A	
  summary	
  of	
  demographics	
  and	
  baseline	
  characteristics	
  wil l	
  be	
  presented	
  by	
   treatment	
  arm 	
  and	
  overall	
  
for	
   the	
   ITT 	
  and	
   safety	
   population s.	
  The	
   demographic	
  characteristics	
  will 	
  consist	
   of	
   age,	
   sex,	
   ethnicity, 	
  
and	
  race 	
  using	
  descriptive	
  statistics. 	
  
	
  
Demographic	
  data	
  including	
  age,	
  race,	
  ethnicity,	
  and	
  gender,	
  as	
  wel l	
  as	
  baseline	
  clinical	
  characteristics	
  
will	
  be	
  summarized.	
   Age	
  will	
  be	
  calculated	
  based	
  on	
  the	
  following	
  conditional	
  algorithm:	
   	
  
•  Has	
  the	
  patient	
  had	
   his/her 	
  birthday	
  this	
  year? 	
  
o  Yes,	
  then	
  AGE	
  =	
  (year	
  of	
  informed	
  consent)	
   –	
  (year	
  of	
  birth). 	
  
o  No,	
  then	
  AGE	
  =	
  (y ear	
  of	
  informed	
  consent)	
   –	
  (year	
  of	
  birth)	
   –	
  1.	
  
	
  
Clinical	
   baseline	
   characteristics 	
  (including	
   height,	
   weight	
   and	
   body	
   mass	
   index	
   [ BMI]),	
   psychosocial	
  
history ,	
  and	
  substance	
  abuse	
  treatment	
  history	
   will	
  be	
  summarized	
  by	
  treatment	
  group	
  and	
  overall. 	
  
7.3   MEDICAL	
   HISTORY 	
  
Medical	
  history	
  will	
  be	
  coded	
  using	
  MedDRA	
  dictionary 	
  Version	
   18.	
  Medical	
  history 	
  will	
  be	
  present ed.	
  	
  	
  
	
  
8.0   PRIOR 	
  AND 	
  CONCOMITANT 	
  MEDICATIONS 	
  
All	
  medications	
  recorded	
  on	
  the	
  CRFs	
  will	
  be	
  coded	
  using	
  the	
   WHO	
  DRU G	
  Dictionary	
  Enhanced	
  March	
  
2015 .	
  Prior	
  an d	
  concomitant	
  medications	
  will	
  be	
  summarized	
  by	
   treatment	
  arm 	
  in	
  the	
   safety	
  population 	
  
by	
  anatomical	
  therapeutic	
  chemical 	
  Class	
  Level	
  4	
  and	
  WHO	
  Drug	
  base	
  substance	
  preferred	
  name. 	
  
	
  
Prior	
   medications	
   are	
   defined	
   as	
   medications	
   with	
   stop	
   date s	
  occurring	
   befo re	
  the	
   date	
   of	
   first	
  
administration	
  of	
  any	
  study	
  treatment 	
  component .	
  Concomitant	
  medications	
  are	
  defined	
  as	
  medications	
  
with	
  start	
  dates	
  occurring	
  on	
  or	
  after	
   the	
  date	
  of	
   first	
  administration	
  of	
  any	
  study	
  treatment	
  component 	
  
and	
   no	
  more	
  than	
  30	
  days	
  after 	
  the	
  last	
   administration	
  of	
  any	
  study	
  treatment	
  component .	
  Medications	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   11	
  of	
  27	
   	
  with	
  start	
  and	
  stop	
  dates	
  that	
  bracket	
  the	
  date	
  of	
  first	
   administration	
  of	
  any	
  study	
  treatment	
  component	
  
will	
  be	
  summarized	
  as	
  both	
  prior	
  and	
  concomitant	
  medications. 	
  
	
  
Medications	
  that	
   clearly	
  stopped	
  prior	
  to	
  date	
  of	
  first	
   administration	
  of	
  any	
  study	
  treatment	
  component 	
  
will	
  be	
  included	
  in	
  the	
  prior	
  medications	
  table,	
  and	
  medications	
  that	
  clearly	
  started	
  on	
  or	
  after	
  date	
  of	
  
first	
   administration	
  of	
  any	
  study	
  treatment	
  component 	
  will	
  be	
  i ncluded	
  in	
  the	
  concomitant	
  medications	
  
table.	
  All	
  other	
  medications	
  will	
  be	
  included	
  in	
  both	
  the	
  prior	
  and	
  concomitant	
  medications	
  tables. 	
  
	
  
Prior	
  and	
   concomitant	
  medication	
  will	
  be	
  summarized	
  for	
  the	
  safety	
  population. 	
  
	
  
9.0   EFFICACY	
  ANALYSES 	
  
9.1   PRIMARY	
  EFFICACY	
  V ARIABLE	
   –	
  RESPONDER	
  RATE 	
  
The	
  responder	
  definition	
  will	
  be	
  derived	
  based	
  on	
  urine	
  samples	
  obtained	
  from	
  Weeks	
  10,	
  11,	
  12	
  and	
  13	
  
in	
  Phase	
  1	
  and	
  samples	
  obtained	
  at	
  Weeks	
  17	
  ( end	
  of	
   Month	
  1 	
  of	
  Phase	
  2 ),	
  21	
  ( end	
  of	
  Month	
  2	
  of	
   Phase	
  
2)	
  and	
  25	
  ( end	
  of	
  Month	
  3	
  of 	
  Phase	
  2 )	
  and	
  at	
  the	
  3	
  random	
  samples	
  in	
  Phase	
  2.	
   	
  
	
  
To	
  be	
  a	
  responder	
  for	
  Phase	
  1,	
  the	
  subject	
  must	
  have	
  no	
  evidence	
  of	
  illicit	
  opioids	
  use	
  at	
  Week	
  13	
  and	
  
have	
  no	
  evidence	
  of	
  illicit	
  opioids	
  use	
   for	
  at	
  least	
   2	
  out	
  of	
  the	
  three	
  weeks	
  from	
  Week	
  10	
  to	
  Week	
  12 .	
  To	
  
be	
  a	
  responder	
  for	
  Phase	
  2,	
  the	
  subject	
  must	
  have	
  no	
  evidence	
  of	
  illicit	
  opioids	
  use	
  at	
  Month	
  6	
  and	
  have	
  
no	
   evidence	
   of	
   illicit	
   opioids	
   use	
   in	
  5	
   out	
   of	
   the	
   6	
   illicit	
   opioids	
   use	
   assessments	
   in	
   Phase	
   2.	
   To	
   be	
   a	
  
responder	
  for	
  the	
  study,	
  the	
  subject	
  must 	
  be	
  a	
  responder	
  for	
  both	
  Phases	
  1	
  and	
  2. 	
  	
  
	
  
Please	
   note	
   that	
   EMA	
   requested	
   percent	
   negative	
   urine	
   samples	
   as	
   the	
   primary 	
  endpoint	
   for	
   their	
  
evaluation.	
  	
  Percent	
  negative	
  urine	
  samples 	
  is	
  the	
  first	
  secondary	
  endpoint 	
  (see	
  Section	
  9.2.1 )	
  for	
  this	
  
study .	
  
9.1.1   DERIV ATION	
  OF	
  RESPONSE	
  RA TE	
  
For	
  the	
  purpose	
  of	
  deriving	
  the	
   RR,	
  the	
  following	
  rules	
  will	
  be	
  used: 	
  
	
  
Time	
   Window s	
  for	
  Illicit	
  Opioid	
  Use	
  Assessment 	
  
For	
  easy	
  discussion,	
  u nless	
  otherwise	
  stated 	
  a	
  window	
   denoted 	
  as	
  Week	
   (x+,	
  y)	
  for	
  efficacy	
  assessment	
  
is	
  a	
  window	
   that	
  cover s	
  a	
  period	
  between	
  Week	
  x	
   +1	
  day	
   to	
  Week	
  y	
  day	
  (ex clusive	
  of	
  Week 	
  x	
  day	
  but	
  
inclusive	
   of	
   Week 	
  y	
   day).	
   A	
   window	
   denoted	
   as	
   Week s	
  x-­‐y	
   for	
   efficacy	
   assessment	
   is	
   a	
   window	
   that	
  
covers	
  a	
  period	
  between	
  Week	
  x	
  day	
  to	
  Week	
  y	
  day	
  (inclusive	
  of	
  Week	
  x	
  day	
   and	
  Week	
  y	
  day).	
  	
   	
  
	
  
Subjects	
  will	
  receive	
   12	
  weekly	
  injection s	
  from	
  Week	
  1	
   (Day	
  1	
  Week	
  1)	
   through	
  Week	
  12.	
  	
  Subjects	
  will	
  
then	
  receive	
  three 	
  monthly	
  injection s	
  at	
  Week	
  13,	
  Week	
  17,	
  and	
  Week	
  21 .	
  	
  Since	
  the	
  last	
  weekly	
  dosing	
  
will	
  occur	
  at	
  Week	
  12,	
  the	
  e fficacy	
  assessments	
   collected	
  at	
  Week	
  13	
  reflected	
  effects	
  of	
  weekly	
  dosing	
  
in	
  Phase	
  1.	
  	
  The	
  Phase	
  1	
  window	
  is	
  Week	
   (1+,	
  13).	
  	
  Since	
  the	
  last	
  monthly	
  dosing	
  will	
  occur	
  at	
  Week 	
  21	
  
Phase	
  2	
  efficacy	
  window	
  will	
  be	
  Week	
   (13+,	
  25).	
  
	
  
Due	
  to	
  visit	
  date	
  deviation,	
  the 	
  actual	
  days	
  in	
   Phase	
  1	
  and	
  Phase	
  2 	
  may	
  not	
  be	
  exactly	
  equal	
  to	
   91	
  days	
  
(13	
   weeks)	
   and	
   84	
   days 	
  (12	
   weeks),	
   respectively .	
   Similarly,	
   for	
   analysis	
   purpose,	
   weekly	
   and	
   monthly	
  
windows	
  will	
  be	
  based	
  on	
  the	
  visit	
  windows,	
  instead	
  of	
   exact	
   7-­‐day	
  and	
  exact 	
  30-­‐day	
  windows. 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   12	
  of	
  27	
   	
  	
  
Evidence	
  of	
  Illicit	
  Opioid	
  Use	
  within	
  a	
   Window 	
  
Subject	
   response	
   for 	
  Phase	
   1	
   will	
   be	
   based	
   on	
   the	
   12 	
  scheduled	
   weekly	
   post -­‐baseline	
   urine	
   samples	
  
collected	
   from	
   Week s	
  2-­‐13.	
   Subject	
   response	
   for	
   Phase	
   2	
   will	
   be	
   based	
   on	
   the	
   3	
   scheduled	
   monthly	
  
urine	
   samples	
   collec ted	
  at	
  Weeks	
  17,	
  21,	
  and	
  Week	
  25 	
  and	
   the	
  3	
   random	
   samples.	
   Evidence	
   of	
   illicit	
  
opioid	
  use	
  within	
  a	
   window	
  is	
  defined	
  as	
  a	
  positive	
  opioid	
  urine	
  toxicology	
  result	
  or	
  self -­‐reported	
  illicit	
  
opioid	
  use	
  within	
  that	
  window,	
  including	
  the	
  results 	
  from	
  random	
  urine	
  toxicology	
  samples	
   (in	
  Phase	
  2)	
  
obtained	
   within	
   that	
   window.	
   T herefore,	
   there	
   is	
   evidence	
   of	
   illicit	
   opioid	
   use,	
   if	
   self -­‐reported	
   illicit	
  
opioid	
  use	
  is	
   present ,	
  regardless	
  of	
  the	
  opioid	
  urine	
  toxicology	
  result	
  is	
  positive	
  or	
  negative.	
  	
   	
  
	
  
If	
  urine	
   toxicology	
   samples	
   are	
   missing ,	
   for	
   example,	
   due	
   to 	
  missing	
   scheduled	
   visit, 	
  early	
  
discontinuation	
  of	
  the	
  study ,	
  or	
  subject’s	
   refusal	
   to	
  provide	
  the	
  samples 	
  (scheduled	
  or	
  random	
  samples) ,	
  
the	
   result s	
  will	
   be	
   imputed	
   as	
   positive	
   according	
   to	
   the	
   Missing	
   Value	
   Imputation	
   rules	
   discussed	
   in	
  
Section	
  9.1.3	
  of	
  the	
  SAP .	
  	
  	
  
9.1.2   PRIMARY	
  ANALYSIS 	
  
The	
  primary	
  analysis	
  of	
   RR	
  will	
  be	
  performed	
   based	
  on 	
  the	
  ITT	
  population. 	
  	
  	
  
	
  
An	
  analysis 	
  of	
  non -­‐inferiority	
  in 	
  the	
  primary	
  efficacy	
  variable 	
  between	
  the	
  two	
  treatments	
   arms	
  will	
  be	
  
performed	
  using	
  a	
   margin	
  of	
   10%	
  point .	
  	
  
	
  
Non-­‐inferiority	
  will	
  be	
  concluded	
  if 	
  the	
  two -­‐sided	
  95%	
  confidence	
  interval	
  for	
  the	
  difference	
  between	
  
the	
  probabilities	
  of	
  response 	
  (Active -­‐	
  Control)	
   is	
  above	
   –0.10.	
  The	
  95%	
  confidence	
  interval ,	
  (LB,	
  UB ),	
  will	
  
be	
  derived	
  using	
  normal	
  approximation :	
  
	
  
LB	
  =	
  (PT-­‐PC)	
  –	
  1.96*(1/N T*PT*(1-­‐PT)+	
  1/N C*PC*(1-­‐PC))0.5	
  ,	
  and 	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
   UB	
  =	
  (PT-­‐PC)	
  +	
  1.96*(1/N T*PT*(1-­‐PT)+	
  1/N C*PC*(1-­‐PC))0.5,	
  where 	
  	
  	
  	
  
	
  
PT	
  and	
  P C	
  are	
  observed	
  proportions	
  of	
  the 	
  responders	
  for	
  the	
  treatment	
  and	
  the	
  control,	
  respectively,	
  
and	
  N T	
  and	
  N C	
  are	
  the	
  sample	
  sizes	
  for	
  the	
  treatment	
  and	
  the	
  control,	
  respectively. 	
  
9.1.3   MISSING	
  VALUE	
  IMPUTA TION 	
  
Unless	
  otherwise	
  stated	
  the	
  following	
  procedures	
  will	
  be	
  used 	
  to	
  handle	
  missing	
  values 	
  for	
  urine	
  
toxicology .	
  	
  	
  
	
  
All	
  missing	
   urine	
  toxicology 	
  samples 	
  (scheduled	
  or	
  random 	
  samples) ,	
  regardless	
  of	
  reasons, 	
  will	
  be	
  
imputed	
  as	
  positive .	
  	
  
	
  
Unless	
  otherwise	
  stated	
  all	
  other	
  missing	
  values	
  will	
  not	
  be	
  imputed. 	
  
9.2   SECONDARY	
  EFFICACY	
   VARIABLES 	
  
Secondary 	
  efficacy	
  variables	
  will	
  include :	
  	
  
	
  
•  Cumulative	
  Distribution	
  Function	
  ( CDF)	
  of	
  percent	
   urine	
  samples	
  negative	
  for	
  illicit	
  opioids 	
  
(supported	
  by	
  self -­‐reported	
   illicit	
  opioids 	
  use	
  results) 	
  based	
  on	
   Week s	
  5-­‐25;	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   13	
  of	
  27	
   	
  •  Time	
  to	
  sustained	
  abstinence	
  of	
  opioid	
  use 	
  (suppo rted	
  by	
  self -­‐reported	
   illicit	
  opioids 	
  use	
  
results) ;	
  	
  
•  Percent	
  of	
  subjects	
  remaining	
  in	
  the	
  study	
  ( retention	
   rate);	
  
	
  	
  	
  
9.2.1   CUMULATIVE	
  DISTRIBUTI ON	
  FUNCTION	
  (C DF)	
  OF	
  PERCENT	
  SAMPLES	
  
THAT	
  ARE	
  NEGATIVE	
  FO R	
  ILLICIT	
  OPIOIDS	
   (WEEKS	
   5-­‐‑25)	
  
Percent	
   negative	
   samples	
   from	
   15	
  samples	
  ( 9	
  weekly	
  assessments	
   obtained	
  from	
   Weeks 	
  5	
  to	
  13,	
   plus	
   3	
  
monthly	
  assessments	
  obtained	
  at	
  Weeks	
   17,	
  21,	
  and	
  25 	
  and	
   plus	
   3	
  random	
  samples )	
  will	
  be	
  calculated	
  
for	
  each	
  subject.	
  	
  Missing	
  samples	
  will	
  be	
  imputed	
  as	
  positive	
  before	
  the	
  percentage	
  is	
   derived. 	
  	
  	
  
	
  
The	
   null	
  hypothesis	
   of	
  no	
  difference	
  in	
  the	
  CDF	
  of	
  the	
  percent	
  of	
  urine	
  samples	
  that	
  are	
  negative	
  for 	
  
illicit	
  opioids	
  over	
   Weeks	
   5-­‐25	
  will	
  be	
  tested 	
  at	
  the	
  5%	
  significance	
  level	
  using	
   Wilcoxon	
  Rank -­‐Sum 	
  test.	
  
The	
  empirical	
  CDF	
  plot	
  will	
  be	
  prese nted. 	
  	
  	
  
9.2.2   TIME	
   TO	
  SUSTAINED	
  ABSTINE NCE	
  OF	
  OPIOID	
  USE 	
  	
  
For	
  the	
  purpose	
  of	
  deriving	
   time	
  to	
   sustained	
   abstinence	
  of	
  opioid	
  use	
  (i.e.,	
  no	
  opioid	
  use	
  through	
  the	
  
rest	
  of	
  treatment	
  period	
  for	
  at	
  least	
  two	
  months) ,	
  the	
  time	
  will	
  be	
  define d	
  as:	
  
	
  
•  If	
  the	
   sustained	
  ab stinence 	
  is	
  obtained	
  during	
  the	
  scheduled	
  visit,	
  time	
  is	
  the	
  number	
  of	
  days	
  
between	
   randomization	
   day	
   to	
   the	
   scheduled	
   visit	
   day.	
   	
   For	
   example,	
   if	
   first	
   sustained	
  
abstinence 	
  is	
  obtained	
   at	
  the 	
  Week	
  8	
  visit,	
  the	
  time	
  would	
  be	
  56. 	
  
•  If	
  the	
   first	
  sustained	
  abst inence 	
  is	
  obtained	
  during	
   a	
  random	
  test,	
  time	
  is	
  the	
  number	
  of	
  days	
  
between	
  randomization	
  day	
  to	
  the	
  day	
  that	
  random	
  sample	
  is	
  obtained	
  (Random	
  Sample	
  Date	
   –	
  
Randomization	
  Date).	
  	
   	
  
	
  
The	
  same	
  definition	
  for	
  evidence	
  of	
  illicit	
  opioid	
  use	
  (see	
  Section	
  9.1.1) 	
  and	
  the	
  same	
  rules	
  for	
  missing	
  
value	
  imputation	
  (see	
  Section	
  9.1.3)	
  will	
  be	
  used	
  in	
  the	
  calculation.	
   	
  
	
  
Time	
  to	
  sustained	
  abstinence	
  of	
  opioid	
  use 	
  will	
  be	
  analyzed	
  via	
   a	
  log-­‐rank	
  model	
  with	
  treatment	
  effects.	
  
Time	
  to	
  event	
  “Survival”	
  curve	
  will	
  be	
  presente d	
  using	
  Kaplan -­‐Meier	
  method.	
  Median	
  time	
  to	
  event	
  and	
  
the	
  95%	
  confidence	
  interval	
  of	
  the	
  median	
  times	
  will	
  be	
  presented,	
  if	
  estimable.	
  In	
  this	
  time	
  to	
  event	
  
analyses,	
  subjects	
  who	
  do	
  not	
  have	
  any	
  opioid -­‐positive	
  results	
  during	
  the	
  entire	
  study	
  and	
  who	
  do	
  n ot	
  
have	
  any	
  opioid -­‐positive	
  results	
  before	
  discontinuing	
  from	
  the	
  study	
  will	
  be	
  censored	
  at	
   Day	
   175	
  
(Week 	
  25	
  day),	
   the	
  day	
  when	
  the	
  last	
  sample	
   will	
  be 	
  obtained. 	
  
9.2.3   PERCENT	
  OF	
  SUBJECTS	
   REMAINING	
  IN	
  THE	
  STU DY	
  (RETENTION	
   RATE) 	
  
The	
  percentages	
  for	
  each	
  treatment 	
  and	
  between	
  treatment	
  percentage	
  differences	
  will	
  be	
  estimated.	
  
The	
  95%	
  confidence	
  intervals	
  of	
  the	
  estimated	
  treatment	
  differences ,	
  based	
  on	
  a	
  normal	
  approximation, 	
  
will	
  be	
  presented. 	
  In	
  addition,	
  t he	
  retention	
  rate	
  will	
  be	
  analyze d	
  using	
  a	
  chi	
  square	
  te st.	
  	
  
	
  
An	
  analysis 	
  of	
  non -­‐inferiority	
  in	
  th is	
  variable	
  between	
  the	
  two	
  treatments	
  arms	
  will	
  be	
   performed	
  using	
  
a	
  margin	
  of	
   15%	
  point .	
  Non-­‐inferiority	
  will	
  be	
  concluded	
  if 	
  the	
  two -­‐sided	
  95%	
  confidence	
  interval	
  for	
  the	
  
difference	
   in	
  retention	
  rate 	
  (Active -­‐	
  Control)	
   is	
  above 	
  15%. 	
  
9.3   EXPLORATORY 	
  EFFICACY	
   VARIABLES 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   14	
  of	
  27	
   	
  	
  
Exploratory	
   efficacy	
  variables 	
  will	
  include :	
  
•  Primary	
  endpoint	
   RR	
  for	
  Phase	
  1 ;	
  
•  Primary	
  endpoint	
   RR	
  for	
  Phase	
  2 ;	
  
•  Percentage	
  negative	
  urine	
  samples	
  in	
  Phase	
  1;	
   	
  
•  Percentage	
  negative	
  urine 	
  samples 	
  in	
  Phase	
   2;	
  
•  Percent	
  of	
  subjects	
  with	
  evidence	
  of	
  n o	
  illicit	
  opioid	
  u se	
  by	
   time	
   point;	
  
•  Cumulative	
   percentage	
  of	
   subjects	
  with	
  e vidence	
  of	
   no	
  illicit	
  opioid	
  u se	
  after	
  two	
   months	
  of	
  
treatment	
   by	
  time	
  point 	
  (from	
  Week	
  9	
  to	
  Week	
  25) ;	
  
•  Percent	
  of	
   subjects	
  with	
  n o	
  self-­‐repor ted	
  illicit	
  opioid	
  u se	
  by	
   time	
  point ;	
  
•  Percent	
  of	
  subjects	
  meeting	
  criteria	
  of	
  stability	
   at	
  Week	
  13 ;	
  
•  Measures	
  of	
  craving:	
  Desire	
  to	
  Use	
   visual	
  analog	
  scale	
  ( VAS)	
  and	
   Need	
  to	
  Use	
  VAS ;	
  
•  Measures	
  of	
  withdrawal:	
  Clin ical	
  Opiate	
  Withdrawal	
  Scale	
  (COWS) 	
  and	
   Subjec tive	
  Opiate	
  
Withdrawal	
  Scale	
  (SOWS) ;	
  	
  
•  Percent	
  of	
  subjects	
   without 	
  evidence	
  of	
   using	
   other	
  drugs	
  of	
  abuse	
   by	
  time	
  point ;	
  
•  Supplemental	
  BPN	
  use ;	
  
•  Additional	
  supplemental	
  counseling ;	
  
•  Measures	
  of	
  morning	
   need	
  to	
  use/desire	
  to	
  use 	
  
9.3.1   RESPONSE 	
  RATE	
  (RR)	
  FOR	
  PHASE	
   1	
  	
  
The	
  treatment	
  differences	
  in	
  RR	
   based	
  on	
  the	
  primary	
  responder	
  definition	
  and	
  based	
  on	
   responder	
   for	
  
Phase	
   1 	
  will	
   be	
   analyzed 	
  using	
   chi 	
  square	
   test .	
   The	
   percentages	
   for	
   each	
   treatment	
   and	
   between	
  
treatment	
  percentage	
  differences	
  will	
  be	
  estimated.	
  The	
  95%	
   confidence	
  intervals	
  of	
  the	
  estimates	
  will	
  
be	
  presented 	
  using	
  normal	
  approximation .	
  
9.3.2   RESPONSE	
  RATE	
  (RR)	
  F OR	
  PHASE	
  2 	
  	
  
The	
  treatment	
  differences	
  in	
  RR	
   based	
  on	
  the	
  primary	
  responder	
  definition	
   for	
  Phase	
  2 	
  will	
  be	
   analyzed 	
  
using	
   chi 	
  square	
   test .	
   The	
   percentage s	
   for	
   each	
   treatment	
   and	
   between	
   treatment	
   percentage	
  
differences	
   will	
   be	
   estimated.	
   The	
   95%	
   confidence	
   intervals	
   of	
   the	
   estimates	
   will	
   be	
   presented 	
  using	
  
normal	
  approximation .	
  
9.3.3   PERCENTAGE	
  NEGATIVE	
   URINE	
  SAMPLES	
  IN 	
  PHASE	
  1 	
  (WEEKS	
  3 -­‐‑13)	
  
The	
  percentages	
  for	
  e ach	
  treatment	
  and	
  between	
  treatment	
  percentage	
  differences	
  will	
  be	
  estimated 	
  
for	
  Phase	
  1 .	
  The	
  95%	
  confidence	
  intervals	
  of	
  the	
  estimated	
  treatment	
  differences ,	
  based	
  on	
  a	
  normal	
  
approximation, 	
  will	
  be	
  presented. 	
  In	
  addition,	
  t he	
  percentage	
  negative	
  urine	
  sa mples 	
  will	
  be	
  analyze d	
  
using	
  a	
  chi	
  square	
  test. 	
  
9.3.4   PERCENTAGE	
  NEGATIVE	
   URINE	
  SAMPLES	
  IN 	
  PHASE	
  2 	
  (WEEKS	
  14 -­‐‑25)	
  
The	
  percentages	
  for	
  each	
  treatment	
  and	
  between	
  treatment	
  percentage	
  differences	
  will	
  be	
  estimated 	
  
for	
  Phase	
  2 .	
  The	
  95%	
  confidence	
  intervals	
  of	
  the	
  es timated	
  treatment	
  differences ,	
  based	
  on	
  a	
  normal	
  
approximation, 	
  will	
  be	
  presented. 	
  In	
  addition,	
  t he	
  percentage	
  negative	
  urine	
  samples 	
  will	
  be	
  analyze d	
  
using	
  a	
  chi	
  square	
  test. 	
  
9.3.5   PERCENT	
  OF	
  SUBJECTS	
   WITH	
   NO	
  ILLICIT	
  OPIOID	
  USE	
  B Y	
  TIME	
  POINT 	
  	
  
For	
  the	
  purpose	
  of 	
  deriving	
  percent	
   of	
  subjects	
  with	
   no	
  illicit	
   opioid	
   use	
  by	
   month,	
   the	
  same	
  defin itions	
  
for	
  monthly	
  window 	
  and	
   evidence	
  of	
  illicit	
  opioid	
  use 	
  (see	
  Section	
  9.1.1)	
   and	
   the	
  same	
  rules	
  for	
   missing	
  
value	
  imputation	
   (see	
  Section	
  9.1.3) 	
  will	
  be	
   used 	
  in	
  the	
  calcul ation .	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   15	
  of	
  27	
   	
  	
  
The	
   treatment	
   differences	
   in	
   these	
   by	
   month 	
  variables 	
  will	
   be	
   analyzes	
   using	
   chi	
   square	
   tests.	
   The	
  
percentages 	
  for	
  each	
  treatment	
  and	
  between	
  treatment	
  percentage	
  differences	
  will	
  be	
  estimated.	
  The	
  
95%	
  confidence	
  intervals	
  of	
  the	
   estimate s	
  will	
  be	
   presented 	
  using	
  normal	
  approximation .	
  	
  	
  
	
  
The	
  overall	
  treatment	
  difference	
  will	
  be	
  tested	
  via	
   Wei	
  and	
  Lachin 	
  procedure.	
   In	
  this	
  analysis,	
  missing	
  
values	
  were	
  not	
  imputed. 	
  
9.3.6   CUMULATIVE	
  PERCENTAG E	
  OF	
   SUBJECTS	
  WITH	
   EVIDENCE	
  OF	
   NO	
  
ILLICIT	
  OPIOID	
  USE 	
  BY	
  TIME	
  POINT 	
  AFTER	
  2	
   MONTH S	
  OF	
  TREATMENT 	
  
The	
   cumulative	
   percentage	
   of	
   evidence	
   of	
   no	
  illicit	
   opioid	
   use	
   will	
   be	
   calculated	
   for	
   all	
   post	
   basel ine	
  
scheduled	
   visits	
   after	
   two	
   months 	
  of	
   treatment	
   (from 	
  Week	
   9	
  to	
  Week	
   25).	
   The	
   same	
   definition	
   for	
  
evidence	
  of	
  illicit	
  opioid 	
  use	
  (see	
  Section	
  9.1.1)	
  and	
  the	
  same	
  rules	
  for	
  missing	
  value	
  imputation	
  (see	
  
Section	
  9.1.3)	
  will	
  be	
  used	
  in	
  the	
  calculation. 	
  As	
  the	
  percentage	
  is	
  derived	
  on	
  a	
  cumulative	
  basis,	
  subject	
  
will	
  be	
  included	
  in	
  the	
  numerator	
  (i.e.,	
  users)	
  at	
  a	
  given	
  scheduled	
  v isit,	
  if	
  the	
  subjects	
  have	
  evidence	
  of	
  
use	
  at	
  any	
  prior	
  visits	
  or	
  at	
  the	
  current	
  visit. 	
  
	
  
The	
   cumulative	
  percentages 	
  by	
  month	
  will	
  be	
  analyze d	
  using	
  chi	
  square	
  tests.	
  The	
  percentages	
  for	
  each	
  
treatment	
   and	
   between	
   treatment	
   percentage	
   differences	
   will	
   be	
   es timated.	
   The	
   95%	
   confid ence	
  
intervals	
  of	
  the	
  estimated	
  treatment	
  differences 	
  will	
  be	
  presented. 	
  	
  	
  
	
  
The	
   overall	
   treatment	
   difference	
   will	
   be	
   also	
   tested	
   via	
   Wei	
   and	
   Lachin 	
  procedure. 	
  	
  In	
   this	
   analysis,	
  
missing	
  values	
  were	
  not	
  imputed. 	
  
9.3.7   PERCENT	
  OF	
  SUBJECTS	
   WITH	
  NO	
  SELF -­‐‑REPORTED	
  ILLICIT	
   OPIOID 	
  USE	
  
BY	
  TIME	
  POINT 	
  
Percent	
   of	
   s ubjects	
   with	
   No	
   Self -­‐Reported	
   Illicit	
   Drug	
   Use	
   by	
   time	
   p oints	
  (by	
   scheduled	
   post	
   baseline	
  
visit) 	
  will	
   be	
   analyze d	
  using	
   chi	
   square	
   tests.	
   The	
   percentages	
   for	
   each	
   treatment	
   and	
   between	
  
treatm ent	
   percentage	
   differences	
   will	
   be	
   estimated.	
   The	
   95%	
   confi dence	
   intervals	
   of	
   the	
   estimated	
  
treatment	
  differences 	
  will	
  be	
  presented. 	
  
9.3.8   PERCENT	
  OF	
  SUBJECTS	
   MEETING	
  CRITERIA	
  OF	
   STABILITY	
   BY	
  TIME	
  
POINT 	
  
At	
   each	
   weekly	
   visit,	
   starting	
   at	
   Week	
   5,	
   the	
   subjects	
   will 	
  be	
   evaluated	
   with	
   regard	
   to	
   the	
   following	
  
stability	
  criteria: 	
  
•  Has	
  the	
  subject	
  been	
  on	
  a	
  stable	
  dose	
  of	
  CAM2038	
  q1w/Placebo	
  SC	
  injections	
  without	
  any	
  
fluctuations	
  in	
  doses	
  for	
  the	
  last	
  4	
  weeks? 	
  
•  Does	
  the	
  subject	
  exhibit	
  minimal	
  subjective	
  and	
  no	
  objective	
  w ithdrawal	
  symptoms,	
  based	
  on	
  
SOWS	
  ≤7	
  and	
  COWS	
  <5? 	
  
•  Does	
  the	
  subject	
  exhibit	
  diminished	
  desire/need	
  to	
  use,	
  based	
  on	
  VAS	
  scores 	
  (defined	
  as	
  at	
  least	
  
50%	
  reduction	
  from	
  baseline	
  in	
  the	
  VAS	
  score) ?	
  
•  Does	
  the	
  subject	
  exhibit	
  diminished	
  use	
  of	
  illicit	
  opioids,	
  ac cording	
  to	
  the	
  Investigator’s	
  
discretion? 	
  
	
  
Percent	
  of	
  subjects	
  meeting	
  criteria	
  of	
  stability	
  by	
  time	
  point	
  (by	
  scheduled	
  post	
  baseline	
  visit)	
  will	
  be	
  
analyze d	
  using	
  chi	
  square	
  tests.	
  The	
  Week	
  13	
  will	
  be	
  the	
  primary	
  time	
  point.	
  The	
  percentages	
  for	
  each	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   16	
  of	
  27	
   	
  treatment	
   and	
   between	
   treatment	
   percentage	
   differences	
   will	
   be	
   estimated.	
   The	
   95%	
   confidence	
  
intervals	
   of	
   the	
   estimated	
   treatment	
   differences	
   will	
   be	
   presented. 	
  Additionally,	
   f or	
   the	
   primary	
   time	
  
point	
  (Week 	
  13),	
  sensitivity	
  analysis	
  will	
  be	
  performed	
   quantify ing	
  the	
  number	
  of	
  subjects	
  with	
  a t	
  least 	
  
25%	
  reduction	
  in	
  positive	
  urine	
  test	
  performed	
  at	
  Weeks	
  10 -­‐13	
  compared	
  to	
  Weeks	
  2 -­‐5.	
  	
  
	
  
The	
  overall	
  treatment	
  difference	
  will	
  be	
  also	
  tested	
  via	
   Wei	
  and	
  Lachin 	
  procedure. 	
  
9.3.9   MEASURES	
  OF	
  CRAVING 	
  (VAS) 	
  
Meas ures	
  of	
  craving 	
  include 	
  Desire	
  to	
  Use	
  VAS 	
  and	
   Need	
  to	
  Use	
  VAS,	
   will	
  be	
  administered	
  using	
  unipolar	
  
100	
  mm	
  VAS	
  (“In	
  the	
  past	
  week/month,	
  how	
  intense	
  has	
  been	
  your	
  average	
  desire/need	
  to	
  use	
  “drug	
  
name?”,	
  where	
  0	
  =	
  No	
  desire	
  to	
  use	
  and	
  100	
  mm=	
  Strongest	
  possible	
  desire,	
  an d	
  from	
  0=No	
  need	
  to	
  use	
  
and	
   100	
   mm=Strongest	
   possible	
   need,	
   respectively). 	
  	
  They	
   will	
   be 	
  measured	
   at	
   baseline	
   and	
   some	
  
selected	
   post	
   baseline	
   visits	
   (For	
   more	
   detail,	
   please	
   refer	
   to	
   Table	
   3,	
   Schedule	
   of	
   Assessments ,	
   in	
  
Section	
  10	
  of	
  the	
  protocol,	
   TRIAL	
  PR OCEDURES	
  AND	
  ASSESSMENTS ).	
  	
  
	
  
Changes	
  from	
  baseline	
  in	
  the	
   above	
   VASs	
  will	
  be	
  derived	
  by	
  subtracting	
  the	
  baseline	
  values	
  from	
  the	
  
post -­‐baseline	
  values,	
  thus,	
  negative	
  changes	
  are	
  indicative	
  of	
  improvement. 	
  Changes	
  from	
  baseline	
  in	
  
measurements	
  of	
  craving	
   will	
  be	
  analyzed	
  via	
  Analysis	
  of	
  Covariance	
  (ANCOVA)	
  model	
  with	
  treatment	
  
and	
  baseline	
  effects.	
  Treatment	
  effects	
  and	
  treatment	
  differences	
  will	
  be	
  estimated.	
  The	
  two -­‐sided	
  95%	
  
confidence	
  intervals	
   the	
  treatment	
  differences	
  will	
  be	
  presented. 	
  In	
  this	
  primary 	
  analysis,	
  missing	
  values	
  
will	
  be	
  imputed	
  using	
   Last	
  Observation	
  Carried	
  Forward	
  ( LOCF )	
  method. 	
  
9.3.10   MEASURES	
  OF	
  WITHDRAW AL	
  SYMPTOMS 	
  
Measures	
  of	
  withdrawal	
  include	
  COWS	
  and	
  SOWS. 	
  The	
  COWS	
  is	
  comprised	
  of	
  11	
  items	
  each	
  with	
  a	
  score	
  
of	
  0	
  through	
  4.	
  Higher	
  scores	
   are	
  associated	
  with	
  greater	
  withdrawal	
  symptoms.	
  The	
  items	
  are	
  meant	
  to	
  
be	
   objective	
   (e.g.,	
   resting	
   pulse	
   rate)	
   measures	
   of	
   patient’s	
   withdrawal	
   symptoms.	
   The	
   SOWS	
   is	
  
comprised	
   of	
   16 	
  items	
   each	
   with	
   a	
   score	
   of	
   0	
   through	
   4.	
   Higher	
   scores	
   are	
   associated	
   with 	
  greater	
  
withdrawal	
  symptoms.	
  The	
  items	
  are	
  statements	
  which	
  are	
  evaluated	
  by	
  the	
  patient	
  and	
  are	
  there	
  for	
  
subjective	
  (e.g.,	
  I	
  feel	
  anxious,	
  0	
  =	
  not	
  at	
  all,	
  1	
  =	
  a	
  little,	
  2	
  =	
  moderately,	
  3	
  =	
  quite	
  a	
  bit,	
  4	
  =	
  extremely).	
  	
  
Both	
  COWS	
  and	
  SOWS	
   will	
  be	
  measure d	
  at	
  baseline	
  and	
   some	
  selected	
  post	
  baseline	
  visits	
  (For	
  more	
  
detail,	
   please	
   refer	
   to	
   Table	
   3,	
   Schedule	
   of	
   Assessments ,	
   in	
   Section	
   10	
   of	
   the	
   protocol,	
   TRIAL	
  
PROCEDURES	
  AND	
  ASSESSMENTS ).	
  	
  	
  
	
  
If	
  there	
  are	
  >=3	
  (i.e.,	
  >=20%)	
  missing	
  items	
  in	
  the	
  COWS	
  scale	
  at	
   a	
  given	
  visit	
  or	
  >=4	
  (i.e.,	
  >20%) 	
  
missing	
  items	
  in	
  the	
  SOWS	
  scale	
  at	
  a	
  given	
  visit,	
  the	
  COWS/SOWS	
  score	
  for	
  that	
  visit	
  will	
  be	
  missing.	
  If	
  
there	
  are	
  1	
  or	
  2	
  missing	
  items	
  for	
  the	
  COWS	
  assessment	
  then	
  the	
  total	
  of	
  the	
  non -­‐missing	
  items	
  will	
  be	
  
calculated	
   and 	
  the	
   product	
   of	
   the	
   calculated	
   total	
   and	
   11/(11 -­‐	
  #	
   missing)	
   will	
   be	
   used	
   for	
   the	
   COWS	
  
score	
  for	
  that	
  visit.	
  If	
  3	
  or	
  fewer	
  items	
  are	
  missing	
  for	
  the	
  SOWS	
  score	
  then	
  the	
  total	
  of	
  the	
  non -­‐missing	
  
items	
  will	
  be	
  calculated	
  and	
  the	
  product	
  of	
  the	
  calculated	
  tota l	
  and	
  16/(16	
   -­‐	
  #	
  missing)	
  will	
  be	
  used	
  for	
  
the	
  SOWS	
  score.	
  Missing	
  total	
  scores	
  or	
  scores	
  with	
  more	
  than	
  two	
  missing	
  components	
  in	
  COWS,	
  or	
  
more	
  than	
  3	
  missing	
  components	
  in	
  SOWS ,	
  will	
  be	
  imputed	
  using	
   LOCF	
  method .	
  	
  
	
  
Changes	
  from	
  baseline	
  in	
  COWS	
  and	
  SOWS	
   will	
  be	
  derived	
  by	
  subtracting	
  the	
  baseline	
  values	
  from	
  the	
  
post -­‐baseline	
  values,	
  thus,	
  negative	
  changes	
  are	
  indicative	
  of	
  improvement. 	
  Changes	
  from	
  baseline	
  in	
  
measurements	
  of	
  withdrawal	
  will	
  be	
  analyzed	
  via	
  ANCOVA	
  model	
  with	
  treatment	
  and	
  baseline	
  effect s.	
  
Treatment	
  effects	
  and	
  treatment	
  differences	
  will	
  be	
  estimated.	
  The	
  two -­‐sided	
  95%	
  confidence	
  intervals	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   17	
  of	
  27	
   	
  of	
  the	
  treatment	
  differences	
  will	
  be	
  presented. 	
  In	
  this	
  primary	
  analysis,	
  missing	
  values	
  will	
  be	
  imputed	
  
using	
  LOCF	
  method. 	
  
9.3.11   PERCENT	
   OF	
  SUBJECTS	
  WITHOUT 	
  EVIDENCE	
  OF 	
  USING	
  OTHER	
  DRUGS	
  
OF	
  ABUSE	
  BY	
  TIME	
  POI NT	
  
The	
   list	
   of	
   drugs	
   of	
   abuse	
   will	
   include	
   cocaine,	
   benzodiazepines,	
   barbiturates,	
   amphetamines,	
  
phenycyclidine,	
  and	
  THC .	
  Percent	
  of	
  subjects	
  without	
  using	
  each	
  of	
  the	
  above	
  drugs	
  by	
  time	
  point	
   (by	
  
schedul ed	
   post	
   baseline	
   visit)	
   will	
   be	
   analyzed 	
  using	
   chi	
   square	
   tests.	
   The	
   percentages	
   for	
   each	
  
treatment	
   and	
   between	
   treatment	
   percentage	
   differences	
   will	
   be	
   estimated.	
   The	
   95%	
   confidence	
  
intervals	
  of	
  the	
  estimated	
  treatment	
  differences	
  will	
  be	
  presented. 	
  
9.3.12   SUPPL EMENTAL	
  BPN	
  USE 	
  
Supplemental	
   BPN	
   will	
   be	
   provided	
   utilizing	
   CAM2038	
   q1w	
   8	
   mg	
   SC	
   injection	
   only	
   in	
   Phase	
   2.	
  
Supplemental	
   BPN	
   will	
   be	
   allowed	
   at	
   maximum	
   of	
   one	
   SC	
   injection	
   per	
   month	
   (in	
   between	
   two	
  
scheduled	
  clinic	
  visits).	
   	
  
	
  
Percentages	
  of	
  subjects	
  who	
  req uire	
  supplemental	
   uses	
  and 	
  total	
  number	
  of	
  supplemental	
   use	
  episodes 	
  
will	
  be	
  summarized. 	
  
9.3.13   ADDITIONAL	
  SUPPLEMEN TAL	
  COUNSELING 	
  
Percentages	
   of	
   subjects	
   who	
   required	
   additional	
   unscheduled	
   visit s	
  to	
   obtain	
   counseling	
   to	
   manage	
  
withdrawal	
  symptoms	
  or	
  desire	
  to	
  u se	
  illicit	
  opioids	
  during	
   each	
  of	
  the	
  two	
  phases	
  as	
  well	
  as	
  during	
   the	
  
study 	
  will	
   be	
   summarized.	
   In	
   addition,	
   number	
   of	
   unscheduled	
   visit	
   to	
   obtain	
   such	
   counseling	
   during	
  
each	
  of	
  the	
  two	
  phases	
  as	
  well	
  as	
  during	
   the	
  study 	
  will	
  also	
  be	
  summarized. 	
  
	
  
9.3.14   MEASURES 	
  OF	
  MORNING	
  NEED	
  TO	
  USE/ DESIRE	
  TO	
  USE 	
  (VAS) 	
  
Measures	
   of	
   VAS	
   scores 	
  include	
   Morning	
   Desire	
   to	
   Use	
   VAS	
   and	
   Morning	
   Need	
   to	
   Use	
   VAS,	
   will	
   be	
  
administered	
  using	
  unipolar	
  100	
  mm	
  VAS	
  (“In	
  the	
  past	
  week/month,	
  how	
  intense	
  has	
  been	
  your	
  average	
  
desire/need	
  to	
  use	
   “drug	
  name?”,	
  where	
  0	
  =	
  No	
  desire	
  to	
  use	
  and	
  100	
  mm=	
  Strongest	
  possible	
  desire,	
  
and	
  from	
  0=No	
  need	
  to	
  use	
  and	
  100	
  mm=Strongest	
  possible	
  need,	
  respectively).	
  	
  They	
  will	
  be	
  measured	
  
at	
  baseline	
  and	
   some	
  selected	
  post	
  baseline	
  visits	
  (For	
  more	
  detail,	
  please	
   refer	
  to	
  Table	
  3,	
   Schedule	
  of	
  
Assessments ,	
  in	
  Section	
  10	
  of	
  the	
  protocol,	
   TRIAL	
  PROCEDURES	
  AND	
  ASSESSMENTS ).	
  	
  
	
  
Changes	
  from	
  baseline	
  in	
  the	
  above	
  VASs	
  will	
  be	
  derived	
  by	
  subtracting	
  the	
  baseline	
  values	
  from	
  the	
  
post -­‐baseline	
  values,	
  thus,	
  negative	
  changes	
   are	
  indicative	
  of	
  improvement.	
   Changes	
  from	
  baseline	
  in	
  
measurements	
  of	
  craving	
  will	
  be	
  analyzed	
  via	
  Analysis	
  of	
  Covariance	
  (ANCOVA)	
  model	
  with	
  treatment	
  
and	
  baseline	
  effects.	
  Treatment	
  effects	
  and	
  treatment	
  differences	
  will	
  be	
  estimated.	
  The	
  two -­‐sided	
  95% 	
  
confidence	
  intervals	
   the	
  treatment	
  differences	
  will	
  be	
  presented.	
  In	
  this	
  primary	
  analysis,	
  missing	
  values	
  
will	
  be	
  imputed	
  using	
  Last	
  Observation	
  Carried	
  Forward	
  (LOCF)	
  method. 	
  
9.4   INTERIM	
  ANALYSES 	
  
No	
  interim	
  analyses	
  will	
  be	
  performed. 	
  
9.5   ADJUSTMENT S	
  FOR	
   MULTIP LICITY 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   18	
  of	
  27	
   	
  There	
  are	
  a	
  number	
  of	
  hypothesis	
  testings	
   that	
   will	
  be	
  performed	
  for	
  this	
  study.	
   To	
  control	
  overall	
  Type	
  I	
  
error	
   rate	
   at	
   5%,	
   a	
   closed	
   testing	
   procedure	
   will	
   be	
   employed 	
  (Dmitrienko	
   2004,	
   Dmitrienko,	
   Offen,	
  
Westfall	
  2003 ).	
  Specifically,	
  the	
  following 	
  ordered	
  hypotheses	
  will	
  be	
  tested: 	
  
	
  
1.  Superiority	
  for	
   CDF	
  of	
  percent	
  samples	
  that	
  are	
  negative	
  for	
   illicit	
  opioids 	
  (Weeks	
   5-­‐25);	
  	
  
2.  Superiority	
  for	
  the	
  primary	
  efficacy	
  variable,	
  RR	
  ( Weeks	
   2-­‐25);	
  
3.  Superiority	
  of	
  active	
  treatment	
  over	
  the	
  control	
  for	
  time	
  to	
  su stained	
  abstinence 	
  after	
  8	
  weeks	
  
of	
  treatment ;	
  
4.  Non-­‐inferiority	
  with	
  margin	
  of	
  1 5%	
  for	
  retention	
  rate; 	
  
5.  Superiority	
  of	
  active	
  treatment	
  over	
  the	
  control	
  for	
  retention 	
  rate.	
  	
  
	
  
In	
   this	
   procedure,	
   a	
   comparison	
   will	
   be	
   eligible	
   for	
   non-­‐inferiority	
   or	
   superiority 	
  testing	
   only	
   if	
   all	
  
previous	
  comparisons,	
  if	
  any ,	
  were 	
  successfully	
  established	
  at	
  the	
  two -­‐sided	
  5%	
  significance	
  level.	
  	
   	
  
9.6   POWER	
  AND	
   SAMPLE	
   SIZE	
  JUSTIFICATION 	
  
The	
   sample	
   size	
   of	
   approximately	
   190 	
  per	
   treatment	
   arm	
   ( 380	
  total)	
   will	
   provide	
   approximately	
   82 %	
  
power	
   to	
   establish	
   the	
   non -­‐inferiority 	
  with	
   a	
  13.5%	
   non-­‐inferiority	
   margin	
   for	
   the	
   primary	
   efficacy	
  
variable,	
  RR	
  Week s	
  2-­‐25.	
  In	
  the	
  sample	
  size	
  calculation ,	
  it	
  was	
  assumed	
   that	
   the	
  proportion	
  of	
  response	
  
in	
  both	
  the	
   active	
  treatment 	
  arm	
  and	
  control	
  treatm ent	
  arm 	
  is	
  70% .	
  
	
  
10.0   SUMMARIES 	
  OF	
  MEASURES	
  OF	
  SAFET Y	
  
Safety	
   analyses	
   will	
   be	
   performed	
   for	
  the	
   safety	
   population.	
   Safety	
   evaluations	
   will	
   be	
   based	
   on	
   the	
  
incidence,	
  intensity,	
  and	
  type	
  of	
  adverse	
  events 	
  (AEs) ,	
  as	
  well	
  as	
  on	
  clinically	
  significant	
  changes	
  in	
  th e	
  
subject ’s	
  physical	
  examination,	
  vital	
  signs,	
  and	
  clinical	
  laboratory	
  results ,	
  Injection 	
  site	
  examination	
  and	
  
wound	
   care.	
  	
  Safety	
  variables	
  will	
  be	
  tabulated	
  and	
  presented	
  by	
  study	
  drug	
  actually	
  received. 	
  
	
  
Because	
  there	
  is	
  no	
   pre-­‐specified 	
  safety	
  outcome	
   defined	
  in	
  terms	
  of	
  AEs ,	
  clinically	
  relevant	
   laboratory	
  
parameters,	
  or	
  vital	
  signs,	
  a ny	
  formal	
  comparisons	
  between	
  the	
   treatment	
  arms	
   with	
  respect	
  to	
  specific	
  
safety	
  parameters	
  will	
  be	
  post -­‐hoc.	
  
10.1   EXTENT	
  OF	
  EXPOSURE 	
  
Summary	
  statistics	
  (number	
  and	
  percentage) 	
  of	
  weeks	
  of	
  exposure	
  to	
  study	
  drug	
  (i.e.	
  from	
  date	
  of 	
  initial	
  
injection	
  to 	
  4	
  weeks	
  after	
  the	
  last	
  injection )	
  will	
  be	
  tabulated	
  by	
  treatment	
  group.	
   	
  
10.2   ADVERSE	
  EVENTS 	
  
Each	
  AE	
  and	
   serious	
  adverse	
  event	
  ( SAE)	
  term	
  recorded	
  on	
  the	
  CRFs 	
  will	
  be	
  mapped	
  to	
   a	
  primar y	
  system	
  
organ	
   class	
   (SOC) 	
  and	
   a	
   preferred	
   term	
   using	
   the	
   MedDRA	
   dictionary.	
   The	
   investigator	
   will	
   assess	
   AE 	
  
severity	
  and	
   relationship	
  to	
   the	
  study	
  treatment. 	
  
	
  
Columbia	
  Suicide	
  Severity	
  Rating	
  Scale	
  (C -­‐SSRS)	
  will	
  be	
  summarized. 	
  
	
  
A	
  treatment -­‐emergent	
  advers e	
  event	
  (TEAE)	
  is	
  defined	
  as	
  any	
  AE	
  with	
  an	
  onset	
  date	
  on	
  or	
  after	
  date	
  of	
  
randomization, 	
  or	
   any	
   ongoing	
   event	
   on	
   the	
   date	
   of	
   first	
   dose	
   that	
   worsens	
   in	
   severity	
   after	
   date	
   of	
  
randomization .	
  Only	
  TEAEs	
  with	
  an	
  onset	
  date	
  prior	
  to	
  date	
  of	
  last	
  dose	
  +	
  30	
  day s	
  will	
  be	
  tabulated	
  in	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   19	
  of	
  27	
   	
  summary	
   tables.	
   For	
   the	
   purpose	
   calculating	
   treatment	
   emergence	
   and	
   inclusion	
   in	
   summary	
   tables,	
  
incomplete	
  onset	
  dates	
  will	
  be	
  imputed	
  as	
  detailed	
  in	
   Appendix	
  A .	
  	
  	
  
	
  
TEAEs	
  will	
  be	
  summarized	
  by	
  the	
  number	
  and	
  percent	
  of	
   subjects 	
  in	
  each	
  primary	
  SOC	
  and	
  preferred	
  
term.	
   	
   Patients	
   will	
   be	
   counted	
   only	
   once	
   for	
   each	
   primary	
   SOC	
   and	
   each	
   preferred	
   term.	
   Summary	
  
tables	
  of	
   TEAEs	
  by	
  primary	
  SOC,	
  preferred	
  term	
  and	
  intensity	
  will	
  be	
  provided.	
  If	
  a	
   subject 	
  has	
  more	
  than	
  
one	
  AE	
  coded	
  to	
  the	
  same 	
  preferred	
  term,	
  the	
   subject 	
  will	
  be	
  counted	
  only	
  once	
  for	
  that	
  preferred	
  term	
  
by	
   using	
   the	
   event	
   with	
   the	
   highest	
   intensity.	
   Similarly,	
   if	
   a	
   subject 	
  has	
   more	
   than	
   one	
   AE	
   within	
   a	
  
primary	
  SOC	
  category,	
  the	
   subject 	
  will	
  be	
  counted	
  only	
  once	
  in	
  that	
  SOC	
  cate gory	
  by	
  using	
  the	
  event	
  
with	
  the	
  highest	
  intensity.	
  AEs	
  by	
  primary	
  SOC,	
  preferred	
  term	
  and	
  relationship	
  to	
  study	
  drug	
  will	
  be	
  
provided	
  as	
  well.	
  If	
  a	
   subject	
   has	
  more	
  than	
  one	
  AE	
  coded	
  to	
  the	
  same	
  preferred	
  term,	
  the	
   subject 	
  will	
  
be	
  counted	
  only	
  once	
  for	
  th at	
  preferred	
  term	
  by	
  using	
  the	
  most	
  related	
  event.	
  Similarly,	
  if	
  a	
   subject 	
  has	
  
more	
  than	
  one	
  AE	
  within	
  a	
  primary	
  SOC	
  category,	
  the	
   subject 	
  will	
  be	
  counted	
  only	
  once	
  in	
  that	
  primary	
  
SOC	
  category	
  by	
  using	
  the	
  most	
  related	
  event.	
  In	
  addition, 	
  SAEs	
  by	
  primary	
   SOC	
  and	
  preferred	
  term	
  will	
  
be	
  provided.	
  Deaths	
  and	
  SAEs	
  will	
  be	
  summarized	
  similarly	
  to	
  AEs.	
  All	
   TEAE	
  tables	
  will	
  also	
  include	
  the	
  
total	
  number	
  of	
  events,	
  counting	
  multiple	
  events	
  per	
  patient. 	
  
	
  
Injection 	
  related	
  AEs,	
   other	
  (non -­‐injection 	
  related)	
  AEs	
  as	
  w ell	
  as	
  all	
  AEs	
  will	
  be	
  presented	
  by	
  treatment 	
  
group	
  and	
  overall.	
  Summaries	
  of	
  these	
  AE	
  subsets	
  will	
  be	
  presented	
  for	
  the	
  following	
  categories: 	
  
	
  
•  Study	
  drug	
  related 	
  
•  Intensity 	
  
•  Relationship	
  to	
   injection 	
  
•  Possibly	
  study	
  drug	
  related	
  by	
  intensity 	
  
•  Reasonably	
   injec tion	
  related	
  by	
  intensity 	
  
•  Serious 	
  
•  AEs	
  which	
  led	
  to	
   discontinuation 	
  of	
  treatment 	
  
•  SAEs	
  which	
  led	
  to	
   discontinuation 	
  of	
  treatment 	
  
•  AEs	
  occurring	
  in	
  5%	
  or	
  greater	
  of	
  any	
  treatment	
  group	
  (by	
  preferred	
   term )	
  
	
  
In	
  the	
  AE	
  summary,	
   preferred	
  term s	
  within	
  each	
  SOC	
  wil l	
  appear	
  in	
  alphabetical	
  order.	
  	
   	
  
	
  
Frequencies	
  for	
  deaths	
  and	
  hospitalizations	
  will	
  also	
  be	
  summarized	
  by	
  treatment	
  group	
  and	
  overall. 	
  
	
  
To	
  assess	
  the	
  AE	
  profile	
  during	
  the	
  first	
  week	
  of	
  treatment	
  (first	
  week	
  after	
  the	
  randomization),	
   TEAEs	
  
that	
  occur	
  withi n	
  the	
  first	
  week	
  of	
  treatment	
  will	
  be	
  presented.	
   	
  
	
  
Other	
  safety	
  analyses	
  will	
  be	
  performed	
  as	
  appropriate 	
  
10.3   LABORATORY	
  ASSESSMEN TS	
  
Chemistry,	
   hematology,	
   urinalysis	
   and	
   coagulation	
   profile	
   will	
   be	
   assessed	
   at	
   Screening ,	
   Week	
   1 	
  
(baseline) ,	
  Week 	
  12,	
  Week	
  13,	
  W eek	
  17,	
  Week	
  21 	
  and	
   Week	
  25 	
  (see	
  Section	
  10.4.3 	
  in	
  the	
  clinical	
  trial	
  
protocol 	
  for	
  a	
  complete	
  list	
  of	
  parameters	
  to	
  be	
  assessed) .	
  Summary	
  statistics	
   for	
  these	
  parameters	
   will	
  
be	
   presented	
   by	
   visit	
   for	
   the	
   actual	
   value	
   and	
   change	
   from	
   baseline	
   for	
   each	
   test 	
  in	
   each	
   laboratory	
  
category	
  ( hematology,	
   chemistry,	
   urinalysis,	
   and	
   coagulation	
   profile).	
  Shift	
  tables	
  will	
  be	
  presented	
  for	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   20	
  of	
  27	
   	
  shifts	
  from	
  baseline	
  lab 	
  categories 	
  to	
  end	
  of	
  study	
  laboratory	
  category.	
  The	
  three	
  laboratory	
  categories	
  
will	
  be:	
  L	
  ( below	
  lower	
  b ound	
  of	
  normal	
  range ),	
  N	
  (within	
  normal	
  range) ,	
  and	
   H	
  (above	
  high er	
  bound	
  of	
  
normal	
  range) .	
  	
  	
  	
  
The	
   number	
   and	
   percent	
   of	
   subjects	
   experiencing	
   a 	
  value	
   greater	
   than	
   2x	
   and	
   3x	
   the	
   upper	
   limit	
   of	
  
normal	
  (ULN)	
  for	
  ALT 	
  and	
   AST	
   will	
  also	
  be	
  presented	
  for	
  each	
  vi sit	
  and	
  overall	
  (at	
  any	
  visit) .	
  	
  	
  
If	
  applicable,	
  a 	
  listing	
   will	
  also	
  be	
  provide	
  for	
   all	
  subjects	
  experiencing	
  a 	
  value	
  greater	
  than	
  3x	
  the	
  upper	
  
limit	
  of	
  normal	
  (ULN)	
  for	
  ALT	
  or	
  AST	
  and	
  a	
  doubling	
  of 	
  baseline	
  total	
  bilirubin	
  occurring	
  on	
  the	
  same	
  
visit.	
   	
  
If	
  a	
  lab	
  value	
  is	
  reported	
  using	
  a	
  non -­‐numeric	
  qualifier	
  (e.g.,	
  less	
  than	
  (<)	
  a	
  certain	
  value,	
  or	
  greater	
  than	
  
(>)	
  a	
  certain	
  value),	
  the	
  given	
  numeric	
  value	
  will	
  be	
  used	
  in	
  the	
  summary	
  statistics,	
  ignoring	
  the	
  non -­‐
numeric	
  qualifier. 	
  
If	
  a	
  subject 	
  has	
  repeated 	
  laboratory	
  values	
  for	
  a	
  given	
  time	
  point,	
  the	
  value	
  from	
  the	
  first	
  evaluation	
  at	
  
that	
  time	
  point	
  will	
  be	
  used	
  for	
  summarization	
   purposes. 	
  For	
  the	
  purpose	
  of	
  determining	
  baseline,	
  the	
  
last	
  non -­‐missing	
  observation	
   on	
  or	
   prior	
  to	
   randomization 	
  will	
  be	
  used. 	
  The	
   Week	
  25 	
  values	
  will	
  be	
  the	
  
last	
  post -­‐baseline	
  value	
  on	
  or	
  prior	
  to	
   Week	
  25 .	
  
10.4   VITAL	
  SIGNS 	
  
Vital	
  signs	
  will	
  consist	
  of	
  blood	
  pressure	
  (systolic	
  and	
  diastolic	
  blood	
  pressure,	
  mmHg),	
  pulse	
  rate	
  (beats	
  
per	
  minute),	
  and	
  respiratory	
  rate	
  (breaths/min),	
  and	
   body	
  temperature	
   collected	
  while	
  sitting,	
  following	
  
a	
  rest	
  period	
  of	
  at	
  least	
  3	
  minutes.	
  Vital	
  sign 	
  values 	
  and	
  change	
  from	
  baseline	
  in	
  the	
  vital	
  signs	
  will	
  be	
  
summarized	
  for	
  each	
  treatment	
  group. 	
  
10.5   PHYSICAL	
  EXAM INATION 	
  
Number	
  and	
  percent	
  of	
   subjects 	
  with	
  abnorm al	
  physical	
  exam ination 	
  findings	
  at	
  Screening	
   and	
  Week	
  25	
  
will	
  be	
  summarized	
  by	
  body	
  system	
  for	
  each	
  treatment	
  group	
  and	
  overall.	
  Physical	
   examination 	
  data	
  for	
  
each	
   subject 	
  will	
  also	
  be	
  presented	
  in	
  a	
  listing. 	
  
10.6   12-­‐‑LEAD	
  ELECTROCARDIOGR AM	
  (ECG) 	
  
12-­‐Lead	
  ECGs	
  w ill	
  be	
  performed	
  at	
  screening ,	
  Day	
  1,	
  Day	
  8,	
  and	
  all	
  subsequent	
  scheduled	
  visits	
  through	
  
Week	
  25 	
  after	
  the	
  subject	
  has	
  been	
  resting	
  in	
  a	
  recumbent/supine	
  position	
  for	
  at	
  least	
  3	
  minutes.	
  The	
  
ECG	
   variables	
  will	
  include	
  ventricular	
  heart	
  rate	
  and	
  the	
  PR,	
  QRS ,	
  QT,	
  QTcB	
  and	
  QTcF	
  intervals.	
  The	
  ECGs	
  
will	
   be	
   signed	
   and	
   dated	
   by	
   a	
   medically -­‐qualified	
   individual	
   to	
   confirm	
   review	
   of	
   the	
   ECG	
   and	
   verify	
  
whether	
  any	
  abnormalities	
  are	
  clinically	
  significant.	
   	
  
	
  
Number	
   and	
   percent	
   of	
   subjects 	
  in	
   each	
   ECG	
   finding	
   category 	
  (normal,	
   abnormal	
   not	
   clinically	
  
significant,	
  and	
  abnormal	
  and	
  clinically	
  significant),	
  will	
  be	
  summarized	
  for	
  each	
  visit	
  by	
  each	
  treatment	
  
group	
  and	
  overall.	
  Summary	
  statistics	
  will	
  be	
  presented	
  for	
  the	
  actual	
  value	
  and	
  change	
  for	
  each	
  ECG	
  
parameter. 	
  
	
  
The	
  number	
  and	
  percent	
  of	
  subjects	
  with	
  QT,	
  QTcB	
  and	
  QTcF	
  intervals	
  <	
  450	
  msec,	
  450	
  to	
  <480,	
  480	
  to	
  
<500	
   and	
   greater	
   than/equal	
   to	
   500	
   msec	
   at	
   each	
   visit	
   and	
   overall	
   (at	
   any	
   visit)	
   will	
   be	
   summarized.	
  
Additionally,	
  the	
  number	
  and	
  percentage	
  of	
  subjects	
  with	
   changes	
  in	
  these	
  parameters	
  of	
  <30	
  msec,	
  30	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   21	
  of	
  27	
   	
  to	
   <60	
   msec	
   and	
   greater	
   than/equal	
   to	
   60	
   msec	
   will	
   be	
   summarized	
   at	
   each	
   visit	
  and	
   overall	
   (at	
   any	
  
visit) .	
  
10.7   INJECTION 	
  SITE	
  EXAMINATION 	
  
Injection 	
  site	
  reactions	
  can	
  occur	
  with	
   injection 	
  of	
  CAM2038 	
  or	
  placebo.	
  The	
   injection 	
  site	
  will	
  be	
  visually	
  
inspected	
  for	
   evidence	
  of	
  erythema,	
  edema,	
  itching,	
  pain,	
  infection,	
  bleeding,	
  abnormal	
  healing	
  and	
  any	
  
other	
   abnormalities .	
  	
  Summaries	
   of	
  all	
  injection	
  site	
  reactions	
  as	
  well	
  as	
  of	
   clinically	
  significant	
  injection	
  
site	
  react ions	
  will	
  be	
  presented. 	
  
	
  
All	
  AEs,	
   AEs	
  that	
   are	
  associated	
  with	
   injection 	
  procedures ,	
  and	
   other	
  AEs	
  (not	
  associated	
  with	
   injections )	
  
will	
  be	
  summarized. 	
  
	
  
11.0   IDENTIFICATION	
  AND	
  S UMMARY	
  OF	
  PROTOCOL	
  D EVIATIONS 	
  
Major	
  protocol	
  deviations	
  from	
  entry	
  criteria	
  and	
  tre atment	
  compliance	
  will	
  be	
  summarized	
  as	
  far	
  as	
  
they	
  can	
  be	
  extracted	
  from	
  numeric	
  or	
  coded	
  study	
  data. 	
  
	
  
12.0   DATA	
  QUALITY	
  ASSURAN CE	
  
Accurate	
  and	
  reliable	
  data	
  collection	
  will	
  be	
  ensured	
  by	
  verification	
  and	
  cross	
  check	
  of	
  the	
  CRFs	
  against	
  
the	
  investigator’s	
  reco rds	
  by	
  the	
  study	
  monitor	
  (source	
  document	
  verification)	
  and	
  by	
  the	
  maintenance	
  
of	
  a	
  drug –dispensing	
  log	
  by	
  the	
  investigator.	
   	
  Collected	
  data	
  will	
  be	
  entered	
  into	
  a	
  computer	
  database	
  
and	
   subject 	
  to	
  electronic	
  and	
  manual	
  quality	
  assurance	
  procedures. 	
  
	
  
13.0   REFERE NCES 	
  
	
  
1.  L.	
  J.	
  Wei	
  and	
  J.	
  M.	
  Lachin,	
  Sept	
  1984,	
  “Two -­‐Samples	
  Asymptotically	
  Distribution -­‐Free	
  Tests	
  for	
  
Incomplete	
  Multivariate	
  Observations,”	
   Journal	
  of	
  the	
  American	
  Statistical	
  Association,	
  Vol.	
  79,	
  
No.	
  387	
  (Sep.,	
  1984),	
  pp.	
  653 -­‐661	
  
2.  Dmitrienko,	
  Offen,	
  Westf all	
  2003 ,	
  “Gatekeeping	
  strategies	
  for	
  clinical	
  trials	
  that	
  do	
  not	
  require	
  
all	
  primary	
  effects	
  to	
  be	
  significant,”	
  	
  Statistics	
  in	
  Medicine,	
  22:	
  2387 -­‐2400 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   22	
  of	
  27	
   	
  	
  
14.0   APPENDICES 	
  
14.1   APPENDIX	
   A	
  -­‐‑	
  IMPUTATION	
  ALGORITHM 	
  FOR	
  PARTIAL	
  AND	
  MISS ING	
  
DATES	
   	
  
This	
  section	
  describes	
  missing	
  date	
  imputation	
  methods. 	
  
	
  
For	
  Adverse	
  Events 	
  
	
  
If	
  onset	
  date	
  is	
  completely	
  missing,	
  onset	
  date	
  is	
  set	
  to	
  date	
  of	
  randomization. 	
  
If	
  (year	
  is	
  present	
  and	
  month	
  and	
  day	
  are	
  missing)	
  or	
  (year	
  and	
  day	
  are	
  present	
  and	
  month	
  is	
  missing): 	
  
•  If	
  year	
  =	
  year	
  of	
  randomization,	
  then	
  set	
  month	
  and	
  day	
  to	
  month	
  and	
  day	
  of	
  randomization 	
  
•  If	
  year	
  <	
  year	
  of	
  randomization,	
  then	
  set	
  month	
  and	
  day	
  to	
  December	
  31. 	
  
•  If	
  year	
  >	
  year	
  of	
  randomization,	
  then	
  set	
  month	
  and	
  day	
  to	
  January	
  1. 	
  
If	
  month	
  and	
  year	
  are	
  p resent	
  and	
  day	
  is	
  missing: 	
  
•  If	
  year=year	
  of	
  randomization	
  and	
   	
  
•  If	
  month	
  =	
  month	
  of	
  randomization	
  then	
  set	
  day	
  to	
  day	
  of	
  first	
  dose 	
  
•  If	
  month	
  <	
  month	
  of	
  first	
  dose	
  then	
  set	
  day	
  to	
  last	
  day	
  of	
  month 	
  
•  If	
  month	
  >	
  month	
  of	
  first	
  dose	
  then	
  set	
  day	
  to	
  first	
  day	
  of	
  m onth 	
  
•  If	
  year	
  <	
  year	
  of	
  randomization	
  then	
  set	
  day	
  to	
  last	
  day	
  of	
  month 	
  
•  If	
  year	
  >	
  year	
  of	
  randomization	
  then	
  set	
  day	
  to	
  first	
  day	
  of	
  month 	
  
	
  
For	
  all	
  other	
  cases,	
  set	
  onset	
  date	
  to	
  date	
  of	
  randomization .	
  
	
  
Concomitant	
  Medications /Medical	
  History 	
  
For	
  start	
  date 	
  
•  If	
  start	
  date	
  is	
  completely	
  missing,	
  start	
  date	
  will	
  not	
  be	
  imputed. 	
  
•  If	
  (year	
  is	
  present	
  and	
  month	
  and	
  day	
  are	
  missing)	
  or	
  (year	
  and	
  day	
  are	
  present	
  and	
  month	
  
is	
  missing),	
  set	
  month	
  and	
  day	
  to	
  January	
  1. 	
  
•  If	
  year	
  and	
  month	
  are	
  present	
  and	
  day	
  is	
  missing,	
  s et	
  day	
  to	
  1st	
  day	
  of	
  month. 	
  
	
  
For	
  end	
  date 	
  
•  If	
  end	
  date	
  is	
  completely	
  missing,	
  end	
  date	
  will	
  not	
  be	
  imputed. 	
  
•  If	
  (year	
  is	
  present	
  and	
  month	
  and	
  day	
  are	
  missing)	
  or	
  (year	
  and	
  day	
  are	
  present	
  and	
  month	
  
is	
  missing),	
  set	
  month	
  and	
  day	
  to	
  December	
  31. 	
  
•  If	
  year	
  and	
   month	
  are	
  present	
  and	
  day	
  is	
  missing,	
  set	
  day	
  to	
  last	
  day	
  of	
  the	
  month. 	
  
	
  
Note :	
  that	
  if	
  both	
  start	
  and	
  end	
  dates	
  are	
  missing	
  then	
  the	
  medication	
  will	
  be	
  classified	
  as	
  concomitant. 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   23	
  of	
  27	
   	
  	
  
14.2   APPENDIX	
  B 	
  –	
  LIST	
  OF	
  TABLES,	
  LIST INGS,	
  AND	
  FIGURES 	
  	
  
	
  
List	
  of	
  Tables 	
  
Number 	
   Title	
  
TABLE	
  14.1.1.1 	
   Summary	
  of	
   Disposition	
  of	
  Patients	
  (ITT	
  Population)	
   	
  
TABLE	
  14.1.1.2 	
   Summary	
  of	
   Disposition	
  of	
  Patients	
  (Safety	
  Population) 	
  
TABLE	
  14.1.1.3 	
   Summary	
  of	
   Disposition	
  of	
  Patients	
  ( mITT 	
  Population) 	
  
TABLE	
  14.1.1.4 	
   Summary	
  of	
   Disposition	
  of 	
  Patients	
  (Per	
  Protocol	
  Population) 	
  
TABLE	
  14.1.2 .1	
   Summary	
  of	
   Demographics	
   and	
  Baseline	
  Characteristics	
   (Safety	
  Population) 	
  
TABLE	
  14.1.2 .2	
   Summary	
  of	
   Demographics	
   and	
  Baseline	
  Characteristics	
   (ITT	
  Population) 	
  
TABLE	
  14.1.2 .3	
   Summary	
  of	
   Demographics	
   and	
  B aseline	
  Characteristics	
   (Per	
  Protocol 	
  
Population) 	
  
TABLE	
  14.1.4 	
   Summary	
  of	
  Psychiatric	
  History	
  (Safety	
  Population) 	
  
TABLE	
  14.1.5.1 	
   Summary	
  of	
   Prior	
  Medications	
  (Safety	
  Population) 	
  
TABLE	
  14.1.5.2 	
   Summary	
  of	
   Concomitant	
  Medications	
  (Safety	
  Population) 	
  
TABL E	
  14.1.6 	
   Summary	
  of	
   Substance	
  Abuse	
  Treatment	
  History	
  (Safety	
  Population) 	
  
TABLE	
  14.2.1 .1	
   Analysis	
  Results	
  for	
  Primary	
  Efficacy	
  Variable 	
  Responder	
  Rate	
   (ITT	
  Population) 	
  
TABLE	
  14.2.1.2 	
   Analysis	
  Results	
  for	
  Primary	
  Efficacy	
  Variable 	
  Responder	
  Rate	
   (Per	
  Protocol	
  
Population) 	
  
TABLE	
  14.2. 2.1	
   Analysis	
  Results	
  for	
   CDF	
  of	
  Percentage	
  of	
  Urine	
  Samples	
  Negative	
  for	
  Illicit	
  
Opioids	
   Supported	
  by	
  Self -­‐reported	
  	
  Illicit	
  Opioid	
  Use	
  Results	
   Over	
  W eeks	
  5 -­‐25	
  
(ITT	
  Population) 	
  
TABLE	
  14.2.2 .2	
   Analysis	
  Results	
  for	
   CDF	
  of	
  Percen tage	
  of	
  Urine	
  Samples	
  Negative	
  for	
  Illicit	
  
Opioids	
  Supported	
  by	
  Self -­‐reported	
  	
  Illicit	
  Opioid	
  Use	
  Results	
  Over	
  W eeks	
   5-­‐25	
  
(Per	
  Protocol 	
  Population) 	
  
TABLE	
  14.2. 3.1	
   Analysis	
  Results	
  for	
   Time	
  to	
  Sustained	
  Abstinence	
  of	
  Opioid	
  U se	
  (ITT	
  Population) 	
  
TABLE	
  14.2 .3.2	
   Analysis	
  Results	
  for	
   Time	
  to	
  Sustained	
  Abstinence	
  of	
  Opioid	
  U se	
  (Per	
  Protocol 	
  
Population) 	
  
TABLE	
  14.2. 4.1	
   Analysis	
  Results	
  for	
   Percent	
  of	
  Subjects	
  Remaining	
  in	
  the	
  Study	
  (Retention	
  Rate)	
  
(ITT	
  Population) 	
  
TABLE	
  14.2.4 .2	
   Analysis	
  Results	
  for	
   Percent	
  of 	
  Subjects	
  Remaining	
  in	
  the	
  Study	
  (Retention	
  Rate)	
  
(Per	
  Protocol 	
  Population) 	
  
TABLE	
  14.2.5 .1	
   Analysis	
  Results	
  for	
   Response	
  Rate	
  in	
  Phase	
  1	
  Based	
  on	
  Primary	
  Responder	
  
Definition	
   (ITT	
  Population) 	
  
TABLE	
  14.2.5 .2	
   Analysis	
  Results	
  for	
   Response	
  Rate	
  in	
  Phase	
  2	
  B ased	
  on	
  Primary	
  Responder	
  
Definition	
   (ITT	
  Population) 	
  
TABLE	
  14.2.6 .1	
   Analysis	
  of	
  Percentage	
  Negative	
  Urine	
  Samples	
  in	
  Phase	
  1	
  ( ITT	
  Population) 	
  
TABLE	
  14.2.6 .2	
   Analysis	
  of	
  Percentage	
  Negative	
  Urine	
  Samples	
  in	
  Phase	
  2	
  ( ITT	
  Protocol 	
  
Population) 	
  
TABLE	
  14.2. 7	
   Analysis	
  Results	
  for	
  Percent	
  of	
  Subjects	
  with	
   Evidence	
  of	
   No	
  Illicit	
  Opioid	
  Use	
  by	
  
Time	
  Point 	
  (ITT	
  Population) 	
  
TABLE	
  14.2. 8	
   Analysis	
  Results	
  for	
  Cumulative	
  Percentage	
  of 	
  Subjects	
  with 	
  Evidence	
  of	
   No	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   24	
  of	
  27	
   	
  Urine	
  Illicit	
  Opioid	
  Use	
   after	
  2	
  Month	
  of	
  Treatment	
   by	
  Time	
  Point 	
  from	
  Week	
  9	
  
to	
  Week	
  25	
   (ITT	
  Population) 	
  
TABLE	
  14.2. 9	
   Analysis	
  Results	
  for	
  Percent	
  of	
  Subjects	
  with	
  No	
  Self -­‐Reported	
  Illicit	
  Drug	
  Use	
   by	
  
Time	
  Point	
   (ITT	
  Population) 	
  
TABLE	
  14.2.1 0	
   Analysis	
  Results	
  for	
  Percent	
  of	
  Subjects	
   Meeting	
  Criteria	
  of	
  Stab ility	
  by	
  Time	
  
Point	
   (ITT	
  Population) 	
  
TABLE	
  14.2.11 .1	
   Analysis	
  Results	
  for	
   Change	
  from	
  Baseline	
  in	
   Measures	
  of	
  C raving:	
  Desire	
  to	
  Use	
  
VAS	
  (ITT	
  Population) 	
  
TABLE	
  14.2.11 .2	
   Analysis	
  Results	
  for	
   Change	
  from	
  Baseline	
  in	
   Measures	
  of	
  C raving:	
  Need	
  to	
  Use	
  
VAS	
  (I TT	
  Population) 	
  
TABLE	
  14.2. 12	
   Analysis	
  Results	
  for	
   Change	
  from	
  Baseline	
  in	
   Measures	
  of	
  withdrawal:	
  Clinical	
  
Opiate	
  Withdrawal	
  Scale	
  (COWS)	
  (ITT	
  Population) 	
  
TABLE	
  14.2. 13	
   Analysis	
  Results	
  for	
   Change	
  from	
  Baseline	
  in	
   Measures	
  of	
  withdrawal:	
  Subjective	
  
Opiate	
  Withdrawal	
  Scale	
  (SOWS)	
  (ITT	
  Population) 	
  
TABLE	
  14.2.1 4	
   Analysis	
  Results	
  for	
   Percent	
  of	
  Subjects	
  without	
  Evidence	
  of	
  Using	
  Other	
  Drugs	
  
of	
  Abuse	
  by	
  Time	
  P oint	
  (ITT	
  Population) 	
  
TABLE	
  14.2.1 5	
   Analysis	
  Results	
  for	
  Supplemental	
  SL	
  BPN	
   (CAM2038	
  q1w	
  8	
  mg )	
  Use	
   (ITT	
  
Population) 	
  
TABLE	
  14.2.1 6	
   Analysis	
  Results	
  for	
  Additional	
  Supplemental	
  Counseling	
  (ITT	
  Population) 	
  
TABLE	
  14.2.17 .1	
   Analysis	
  Results	
  for	
   Change	
  from	
  Baseline	
  in	
   Measures	
  of	
  Morning	
  Need	
  to	
  Use 	
  
(ITT	
  Population) 	
  
TABLE	
  14.2.17 .2	
   Analysis	
  Results	
  for	
   Change	
  from	
  Baseline	
  in	
   Measures	
  of	
  Morning	
  Desire	
  to	
  U se	
  
(ITT	
  Population) 	
  
TABLE	
  14.3.1 	
   Summary	
  of	
  Treatment	
  Exposure	
  (Safety	
  Population) 	
  
TABLE	
  14.3.2 	
   Summary	
  of	
  Treatment -­‐Emergent	
  Adverse	
  Events	
   (Safety	
  Population) 	
  
TABLE	
  14.3.3 	
   Summary	
  of	
   Columbia	
  Suicid e	
  Severity	
  Rating	
  Scale 	
  (C-­‐SSRS)	
  (Safety	
  Population) 	
  
TABLE	
  14.3.4 .1	
   Summary	
  of	
   Percent	
  of	
  Subjects	
  Who	
  Reported	
  Injection	
  Site	
  Related	
  P ain,	
  
Itching ,	
  Discharge ,	
  Tenderness ,	
  Erythema/R edness ,	
  and	
  S welling 	
  by	
  Time	
  Point	
  
(Safety	
  Population) 	
  
TABLE	
  14.3.4 .2	
   Summary	
  of	
   Injection	
  Site	
  Related	
  P ain	
  Score	
  by	
  Time	
  Point	
   (Safety	
  Population) 	
  
TABLE	
  14.3.4 .3	
   Summary	
  of	
   Frequency	
  of	
  Injection	
  Site	
  Related	
  Erythema/R edness 	
  and	
  S welling 	
  
Severity	
  by	
  Time	
  Point	
   (Safety	
  Population) 	
  
TABLE	
  14.3.5 .1	
   Summary	
  of	
  All	
   Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  System	
  Organ	
  Class	
  and	
  
Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.5 .2	
   Summary	
  of	
  All	
   Injection 	
  Site	
   Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  System	
  
Organ	
  Class	
  and	
  Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.5 .3	
   Summary	
  of	
  All	
   Other	
  (Non	
   Injection 	
  Site	
  Related)	
   Treatment -­‐emergent	
   Adverse	
  
Events	
  by	
  System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.6 .1	
   Summary	
  of	
  All	
   Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  System	
  Organ	
  Class,	
  
Preferred	
  Term,	
  and	
  Intensity	
  (Safety	
   Population) 	
  
TABLE	
  14.3.6 .2	
   Summary	
  of	
  All	
   Injection 	
  Site	
   Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  System	
  
Organ	
  Class,	
  Preferred	
  Term,	
  and	
  Intensity	
  (Safety	
  Population) 	
  
TABLE	
  14.3.6 .3	
   Summary	
  of	
  All	
  Other	
  (Non	
   Injection 	
  Site	
  Related)	
   Treatment -­‐emergent	
   Advers e	
  
Events	
  by	
  System	
  Organ	
  Class,	
  Preferred	
  Term,	
  and	
  Intensity	
  (Safety	
  Population) 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   25	
  of	
  27	
   	
  TABLE	
  14.3.7 .1	
   Summary	
  of	
  All	
   Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  System	
  Organ	
  Class,	
  
Preferred	
  Term,	
  and	
  Relationship	
  to	
  Study	
  Drug	
  (Safety	
  Population) 	
  
TABLE	
  14.3.7 .2	
   Sum mary	
  of	
  All	
   Injection 	
  Site	
   Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  System	
  
Organ	
  Class,	
  Preferred	
  Term,	
  and	
  Relationship	
  to	
  Study	
  Drug	
  (Safety	
  Population) 	
  
TABLE	
  14.3.7 .3	
   Summary	
  of	
  All	
  Other	
  (Non	
   Injection 	
  Site	
  Related)	
   Treatment -­‐emergent	
   Adverse	
  
Events	
  by	
  Sy stem	
  Organ	
  Class,	
  Preferred	
  Term,	
  and	
  Relationship	
  to	
  Study	
  Drug	
  
(Safety	
  Population) 	
  
TABLE	
  14.3.8 .1	
   Summary	
  of	
  All	
  Suspected	
  to	
  Be	
  Drug	
  Related	
   Treatment -­‐emergent	
   Adverse	
  
Events	
  by	
  System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.8 .2	
   Summary	
  of	
  All	
  Suspected	
  to	
  Be	
  Drug	
  Related	
   Injection 	
  Site	
   Treatment -­‐
emergent	
   Adverse	
  Events	
  by	
  System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  (Safety	
  
Population) 	
  
TABLE	
  14.3.8 .3	
   Summary	
  of	
  All	
  Other	
  (Non	
   Injection 	
  Site	
  Related)	
  Suspected	
  to	
  Be	
  Drug	
  Related	
  
Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  
(Safety	
  Population) 	
  
TABLE	
  14.3.9 .1	
   Summary	
  of	
  All	
  Serious	
   Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  System	
  Organ	
  
Class	
  and	
  Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.9 .2	
   Summary	
  of	
  All	
  Ser ious	
   Injection 	
  Site	
   Treatment -­‐emergent	
   Adverse	
  Events	
  by	
  
System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.9 .3	
   Summary	
  of	
  All	
  Other	
  (Non	
   Injection 	
  Site	
  Related)	
  Serious	
   Treatment -­‐emergent	
  
Adverse	
  Events	
  by	
  System	
  Organ	
  Class	
  and	
  Preferr ed	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.10 .1	
   Summary	
  of	
  All	
   Treatment -­‐emergent	
   Adverse	
  Events	
  That	
  Lead	
  to	
  Study	
  
Discontinuation	
  by	
  System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.10 .2	
   Summary	
  of	
  All	
   Injection 	
  Site	
   Treatment -­‐emergent	
   Adverse	
  Events	
  That	
  Lead	
  to	
  
Study	
  Discontinuation	
  by	
  System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  (Safety	
  
Population) 	
  
TABLE	
  14.3.10 .3	
   Summary	
  of	
  All	
  Other	
  (Non	
   Injection 	
  Site	
  Related)	
   Treatment -­‐emergent	
   Adverse	
  
Events	
  That	
  Lead	
  to	
  Study	
  Discontinuation	
  by	
  System 	
  Organ	
  Class	
  and	
  Preferred	
  
Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.11 .1	
   Summary	
  of	
  All	
  Serious	
   Treatment -­‐emergent	
   Adverse	
  Events	
  That	
  Lead	
  to	
  Study	
  
Discontinuation	
  by	
  System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.11. 2	
   Summary	
  of	
  All	
   Injection 	
  Site	
  Serious	
   Treatment -­‐emergent	
   Adverse	
  Events	
  That	
  
Lead	
  to	
  Study	
  Discontinuation	
  by	
  System	
  Organ	
  Class	
  and	
  Preferred	
  Term	
  
(Safety	
  Population) 	
  
TABLE	
  14.3.11 .3	
   Summary	
  of	
  All	
  Other	
  (Non	
   Injection 	
  Site	
  Related)	
  Serious	
   Treatment -­‐emergent	
  
Adverse	
  Eve nts	
  That	
  Lead	
  to	
  Study	
  Discontinuation	
  by	
  System	
  Organ	
  Class	
  and	
  
Preferred	
  Term	
  (Safety	
  Population) 	
  
TABLE	
  14.3.12 	
   Summary	
  of	
  All	
  Deaths	
  and	
  Hospitalizations	
  (Safety	
  Population) 	
  
TABLE	
  14. 4.1.1	
   Summary	
  of	
  Clinical	
  Hematology	
  Data	
  (Safety	
  Population) 	
  
TABLE	
   14.4. 1.2	
   Shift	
  from	
  Baseline	
  in	
  Laboratory	
  Tests:	
  Hematology	
  (Safety	
  Population) 	
  
TABLE	
  14.4. 1.3	
   Shift	
  from	
  Baseline	
  in	
  Laboratory	
  Tests:	
   >	
  3x	
  the	
  Upper	
  Limit	
  of	
  N ormal	
  (ULN)	
  
for	
  ALT ,	
  AST ,	
  and	
   Doubling	
  of	
  Baseline	
  Total	
  B ilirubin 	
  (Safety	
  Population) 	
  
TABL E	
  14.4.2.1 	
   Summary	
  of	
  Clinical	
  Chemistry	
  Data	
  (Safety	
  Population) 	
  
TABLE	
  14.4. 2.2	
   Shift	
  from	
  Baseline	
  in	
  Laboratory	
  Tests:	
  Chemistry	
  (Safety	
  Population) 	
  
TABLE	
  14.4.3.1. 	
   Summary	
  of	
  Clinical	
  Coagulation	
  Profile	
  Data	
  (Safety	
  Population) 	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   26	
  of	
  27	
   	
  TABLE	
  14.4. 3.2	
   Shift 	
  from	
  Baseline	
  in	
  Laboratory	
  Tests:	
  Coagulation	
  Profile	
  (Safety	
  Population) 	
  
TABLE	
  14.4. 4	
   Number	
  (%)	
  of	
  Patients	
  with	
  Abnormal	
  Physical	
  Examination	
  Findings	
  (Safety	
  
Population) 	
  
TABLE	
  14.4. 5	
   Summary	
  of	
  Vital	
  Signs	
  at	
  Each	
  Visit	
  (Safety	
  Population) 	
  
TABLE	
  1 4.4.6.1	
   Summary	
  of	
  12 -­‐Lead	
  ECG	
  Conclusions	
  (Safety	
  Population) 	
  
TABLE	
  14.4. 6.2	
   Summary	
  of	
  12 -­‐Lead	
  ECG	
  Individual	
  Parameters	
  (Safety	
  Population) 	
  
TABLE	
  14.4. 6.3	
   Summary	
  of	
  12 -­‐Lead	
   Categories 	
  (Safety	
  Population) 	
  
TABLE	
  14.4. 7	
   Pregnancy	
  Test	
  (In	
  clinic	
  urine	
   pregnancy	
  test)	
  (Safety	
  Population) 	
  
TABLE	
  14.4. 8	
   Pregnancy	
  Test	
  (Serum	
  pregnancy	
  test)	
  (Safety	
  Population) 	
  
	
  
List	
  of	
  Listings 	
  
	
  
Number 	
   Title 	
  
LISTING	
  16.2.1.1 	
   Patient	
  Meets	
  Inclusion	
  Criteria 	
  (All	
  Subjects) 	
  
LISTING	
  16.2.1.2 	
   Patient	
  Meets	
  Exclusion	
  Criteri a	
  (All	
  Subjects)	
  
LISTING	
  16.2.2 	
   Eligibility	
  for	
  Randomization 	
  (All	
  Subjects)	
  
LISTING	
  16.2.3 	
   Patient	
  Randomization 	
  (All	
  Subjects)	
  
LISTING	
  16.2.4.1 	
   Demographics 	
  (All	
  Subjects)	
  
LISTING	
  16.2.4.2 	
   Medical	
  History 	
  (All	
  Subjects)	
  
LISTING	
  16.2.4.3 	
   Psychiatric	
   History	
   (All	
  Subjects)	
  
LISTING	
  16.2.4.4 	
   Opioid	
  and	
  Substances	
  Abused 	
  (All	
  Subjects) 	
  
LISTING	
  16.2.5.1 	
   Treatment	
  (All	
  Randomized	
  Subjects) 	
  
LISTING	
  16.2.5.2 	
   Injection 	
  Site	
  Examination/	
  Treatment	
  Compliance 	
  (All	
  Subjects) 	
  
LISTING	
  16.2.5. 3	
   Dosing	
  Record 	
  (All	
  Subjects) 	
  
LISTING16.2.6.1 	
   Clinical	
  Opiate	
  Withdrawal	
  Scale	
  (COWS) 	
  (All	
  Subjects) 	
  
LISTING16.2.6. 2	
   Subjective	
  Opiate	
  Withdrawal	
  Scale	
  (SOWS) 	
  (All	
  Subjects)	
  
LISTING16.2.6. 3	
   Opioid	
  Craving	
  VAS 	
  (All	
  Subjects)	
  
LISTING16.2.6. 4	
   Illicit	
  Drug	
  Use	
  Self	
  Report 	
  (All	
  Subjects) 	
  
LISTING16.2.6.5 	
   Psychosocial	
  Counseling 	
  (All	
  Subjects)	
  
LISTING16.2.7.1 	
   Adverse	
  Events 	
  (All	
  Subjects)	
  
LISTING16.2.7. 2	
   Serious	
  Adverse	
  Events	
   (All	
  Subjects)	
  (All	
  Subjects) 	
  
LISTING16.2.7. 3	
   Adverse	
  Events	
  That	
  Lead	
  to	
  Study	
  Drug	
  Discontinuati on	
  (All	
  Subjects)	
  
LISTING16.2.7. 4	
   Adverse	
  Events	
  That	
  Have	
  Death	
  as	
  the	
  Outcome 	
  (All	
  Subjects)	
  
LISTING16.2.7. 5	
   Death	
  Report 	
  (All	
  Subjects)	
  
LISTING16.2.7. 6	
   Prior	
  and	
  Concomitant	
  Medications/Procedures 	
  (All	
  Subjects)	
  
LISTING16.2. 8.1	
   Lab	
  Test	
  Samples 	
  (All	
  Subjects) 	
  
LISTING16.2.8. 2	
   Clinical	
  Hematology 	
  (All	
  Subjects)	
  
LISTING16.2.8. 3	
   Clinical	
  Chemistry 	
  (All	
  Subjects)	
  
LISTING16.2.8. 4	
   Clinical	
  Coagulation	
  Profile 	
  (All	
  Subjects) 	
  
LISTING16.2.8. 5	
   Urine	
  Collection/Toxicology	
  (General) 	
  (All	
  Subjects) 	
  
LISTING16. 2.8.6	
   Urine	
  Toxicology	
  (Illicit	
  Opioids) 	
  (All	
  Subjects)	
  
LISTING16.2.8. 7	
   Pregnancy	
  Test 	
  (All	
  Subjects)	
  
LISTING16.2.8. 8	
   Physical	
  Examination 	
  (All	
  Subjects)	
  
LISTING16.2.8. 9	
   Vital	
  Signs 	
  (All	
  Subjects)	
  
BRAEBURN	
  PHARMACEUTICALS 	
  CONFIDENTIAL 	
   Version	
  1.0 1—4	
  November ,	
  2016 	
  
HS-­‐‑11-­‐‑421	
  Final	
   SAP 	
   Page	
   27	
  of	
  27	
   	
  LISTING16.2.8. 10	
   12-­‐Lead	
  ECG 	
  (All	
  Subjects) 	
  
LISTING16. 2.8.11	
   C-­‐SSRS	
  (All	
  Subjects) 	
  
LISTING16.2.8. 12	
   Patient	
  Disposition 	
  (All	
  Subjects) 	
  
LISTING16.2.8. 13	
   Protocol	
  Deviations 	
  (All	
  Subjects) 	
  
List	
  of	
  Figures 	
  
	
  
Number 	
   Title 	
  
Figure	
  14.1.1 	
   Responder 	
  Rate	
   Per	
  Primary	
  Efficacy	
  Definition	
   (ITT	
  Population) 	
  
Figure	
  14. 1.2	
   CDF	
  of	
  Percent	
  of	
   Urine	
  Samples	
  Negative	
  for	
  Illicit	
  Opioids	
   Weeks	
  5 -­‐25	
  (ITT	
  
Population) 	
  
Figure	
  14.1. 3	
   Time	
  to	
  sustained	
  abstinence	
  of	
  opioid	
  use 	
  (ITT	
  Population) 	
  
Figure	
  14.1. 4.1	
   Change	
  from	
  Baseline	
  in	
  Desire	
  to	
  Use	
  VAS	
   Over	
  Time	
   (ITT	
  Population) 	
  
Figure	
  14.1. 4.2	
   Change	
  from	
  Baseline	
  in	
  Need	
  to	
  Use	
  VAS	
   Over	
  Time	
   (ITT	
  Population) 	
  
Figure	
  14.1. 5.3	
   Change	
  from	
  Baseline	
  in	
   Morning	
   Desire	
  to	
  Use	
  VAS	
   Over	
  Time	
   (ITT	
  Population) 	
  
Figure	
  14.1. 5.4	
   Change	
  from	
  Baseline	
  in	
   Morning	
   Need	
  to	
  Use	
  VAS	
   Over	
  Time	
   (ITT	
   Population) 	
  
Figure	
  14.1. 6	
   Change	
  from	
  Baseline	
  in	
  Clinical	
  Opiate	
  Withdrawal	
  Scale	
  (COWS) 	
  Over	
  Time 	
  
(ITT	
  Population) 	
  
Figure	
  14.1. 7	
   Change	
  from	
  Baseline	
  in	
  Subjective	
  Opi ate	
  Withdrawal	
  Scale	
  (SOWS) 	
  Over	
  Time 	
  
(ITT	
  Population) 	
  
	
  
	
  